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THE THESIS EXPLAINED 
Cdk9 is a member of cyclin-dependent kinases and it is expressed in 
human and murine tissue with high levels in terminally 
differentiated cells. The elevated levels of Cdk9 and its regulatory 
subunits in terminally differentiated cells, together with the fact that 
it is implicated in  the regulation of transcriptional elongation via 
phosphorylation of CTD of RNA polII, distinguishes Cdk9 from the 
other cdks. 
Cyclin partners of CDK9 are cyclin T1, T2a, T2b and K, with a 
formation of a complex, called p-TEF-B. In Hela cells about 80% of 
cellular P-TEFb is composed of cyclin T1 and  the cyclin –
dependent kinase 9 (CDK9), and about 20% of cellular CDK9 is 
complexed to other cyclins, such as cyclin T2a, T2b and  with cyclin 
K.  
It was demonstrated that CdK9 complexed with CyT2a plays a role 
in the activation of myogenic program and Cdk9-CyT2a activity is 
not down-regulated in myotube formation, but its activation 
contributes  to the transcriptional activity MyoD-mediated during 
myogenic program. 
The formation of a multimeric complex, containing cdk9/cyclin T2a 
and MyoD is present in muscle cells during the activation of the 
differentiation program and the N-terminal region of Cdk9 directly 
interacts with the b-HLH region of MyoD, allowing the formation of 
a complex also containing cyclin T2a. 
Recently a 55 kDa protein called CDK9-55 has been identified. This 
isoform presents 117 additional amminoacids residues at the N-
terminal portion of Cdk9-42 and it conserves all molecular features 
of 42 isoform, indeed it associates with CycT phosphorylates CTD 
of RNA polII. 
Cdk9-55 is significantly upregulated in cells induced to 
differentiate, either in C2C12 cells or in satellite isolated cells, and 
it was demonstrated that there is a clear induction of cdk9-55 
expression in injured skeletal muscles.  
Analysis in vivo on limbs at different times of development 
demostrated a different correlation between two CDK9 isoforms: 
CDK9-55 is involved during foetal myogenesis, whereas the CDK9-
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42 is expressed during embrional myogenesis. Study in vitro 
demonstrated that CDK9-55 is the isoform more expressed during 
differentiation both embrional and fetal myoblasts. A new antibody, 
p-CDK9, permitted us to define CDK9-55 as  the active isoform 
during the differentiation. CDK9-55 is also the isoform more 
expressed during the re-innervation process. 
The analysis of different cyclins that  complex with different 
members of kinase proteins showed that in vivo only cyclin K and 
D3 are involved during foetal myogenesis, suggesting their 
interaction with CDK9-55, whereas Cyclin T1, T2, L and H are 
implicated during primary myogenesis, in concomitance with 
CDK9-42 expression. Study in vitro demonstrated that only cyclin 
T2 is involved during the differentiation process for embrional and 
fetal myoblasts. 
Between inhibitory post transcriptional regulator mechanism of 
CDK9 there is the interaction with 7SKsnRNA and HEXIM1, our 
studies, on C2C12 cells, by RIP assay demonstrated that CDK9 
isn’t associated with 7SKsnRNA/Hexim1 during differentiative 
phase, supporting that in differentiation CDK9 is active. 
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1. INTRODUCTION 
 
1.THE SKELETAL MUSCLE 
 
Skeletal muscle is the most abundant tissue in the body of 
vertebrates. The primary functions of skeletal muscle are the 
locomotor activity, the breathing and postural behaviour. Each 
muscles composed of bundles of fascicles, containing 
multinucleated cells called muscle fibers. Every muscle fiber 
contains numerous protein filaments, myofibrils, which are the 
contractile elements of skeletal muscle. Contractile segments of 
myofibrils, termed sarcomeres, are composed of two types of 
myofilaments. Thin filaments are mainly composed of actin 
molecules and thick filaments are made up of myosin molecules. It 
is the movement of the thick and thin filaments in relation to one 
another that produce contraction. 
Skeletal muscle is composed of different fiber types with varying 
anatomical, molecular, metabolic, structural and contractile 
properties.  
Fast contracting fibers have few mitochondria, low myoglobin 
content, high glycolytic and low oxidative metabolism and are 
highly fatigable. Conversely, slow contracting fibers have many 
mitochondria, a high content of myoglobin, high oxidative 
metabolism and fatigue slow. 
Skeletal muscle is a dynamic tissue capable of responding to 
physiological stimuli such as intense physical activity, as well as 
various types of damage through a regenerative response which is 
able to reform the architecture of the muscle cells in a period of two 
weeks (Cossu et al., 2008). 
The ability of skeletal muscle to mediate a regenerative response is 
mainly due to population consisting of mononucleated satellite 
cells. In response to damage or destruction of basal lamina, satellite 
cells are activated and show a significant proliferative activity. The 
satellite cells then fuse to form multinucleated myotubes and some 
of them may be to restore the pool of remaining quiescent satellite 
cells are able to support further process of regeneration. 
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1.2 MURINE MYOGENESIS AND SKELETAL MUSCLE 
PROGENITOR CELLS 
 
Embryonic myogenesis is a multistep process that begins with 
commitment of an embryonic precursors to the myogenic lineage, 
followed by the proliferation of these committed myoblasts that 
differentiated into postmiotic myocytes and finally fusion of 
myocytes to form a multinucleated myotube. As the myotube 
matures, the syncytial cell becomes specialized for its particular 
function, with the bulk of the cytoplasm occupied by the contractile 
apparatus, and where the myotube/myofibre can further grow or 
hypertrophy in response to appropriate stimuli. Postnatal 
myogenesis is a similar process, except that fusion occurs primarily 
between myoblasts and preexisting myotubes, and where the role of 
the embryonic precursor is played by the quiescent satellite cell. 
In the vertebrate body all the skeletal muscles derive from 
progenitors present in the somites, which are established as paraxial 
mesoderm beside the neural tube and nothocord. The somites are 
generated in rostro-caudial direction by segmentation of paraxial 
mesoderm on both sides of the neural tube. Each newly formed 
somite rapidly differentiates into a ventral sclerotome and a dorsal 
dermomyotome. The sclerotome gives rise to the ribs and 
accompanying cartilage, while the dermomyotome contributes to 
both the hepaxial musculature (back and intercostals muscles) and 
the hypaxial musculature (body wall and limb muscles). The 
hypaxial dermomyotome is specified by signals from the dorsal 
ectoderm (Wnt pathway) and the lateral plate mesoderm (Bmp4), 
and produces the hypaxial myotome that forms the limbs, 
diaphragm and body wall muscles. 
Skeletal muscle is formed in different steps, involving different 
myoblasts populations. 
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Fig.1: From A to C is indicated the formation and the differentiation of somites. 
In D is reported the differentiation process, where the somite cell differentiated in 
myotubes (Lodish et al.,2002). 
 
In mice, somitogenesis begins during the eighth day of embryonic 
day (E8 dpc, days post coitum), with the segmentation of somites. 
After segmentation, somites give rise to epithelial dermomyotome 
on the dorsal side and mesenchymal sclerotome on the ventral side. 
The myotome is formed by involution of cells from dermyotome. 
At around E11 in the mouse, embryonic myoblasts invade the 
myotome and fuse into myotubes. During this phase, called primary 
or embrional myogenesis, myogenic progenitors, which have 
migrated from the dermomyotome to the limb, start to differentiate 
into multinucleated muscle fibers, known as primary fibers. 
Embryonic myoblasts are elongated cells that differentiate into 
mononucletaed or oligonucleated myotubes. 
A new phase of myogenesys takes place between E14.5 and E17,5, 
this phase is called secondary or fetal myogensis and involves 
fusion of fetal myoblasts either with each other to give rise to 
secondary fibers and also with primary fibers. Fetal myoblasts are 
triangular shape and proliferate to a limited extent in response to 
growth factors, differentiate into large multinucleated myotubes. 
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It is only at the end of secondary myogenesis that there is a 
formation of the satellite cells, that are mononucleated cells lying 
between the basal lamina and the fiber plasma membrane. Satellite 
cells are normally quiescent and they are activated in post natal life 
after injury, indeed  when the fiber is damaged these cells become 
activated, replicate and then differentiate to form new fibers, thus 
permitting muscle repair. 
Embryonic and fetal myoblasts, thought to generate primary and 
secondary fibers respectively, differ in the morphology of the 
myotubes they generate in vitro and in the myosin heavy chains 
isoforms and muscle enzyme that they express (Barbieri et al., 
1990; Zappelli et al., 1996). They also differ with respect to media 
requirements (White et al., 1975), integrin-extracellular matrix 
interactions, resistance to inhibitors of myogenesis such as phobol 
esters (Cossu et al., 1988) and TGFβ (Causella-De Angelis et al., 
1994). 
The innervation of muscle starts while fibers are still  forming. Each 
muscle fiber is initially innervated by multiple axons, all but one of 
which are subsequently eliminated. 
 
 
 
Fig. 2: Scheme of lineage of  murine development (Biressi et al., 2007) 
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The process of myogenesis is controlled by several myogenic 
transcription factors (MRFs: Myod, Myf5, myogenin and MRF4) 
that act as terminal effectors of signaling cascades and produce 
appropriate developmental stage-specific transcripts.  
The MRF proteins contain the conserved basic domain that is 
essential for the binding of specific DNA sequence and a helix-
loop-helix motif required for heterodimerize. Each of the MRFs has 
shown the ability to heterodimerize both in vitro and in vivo with E 
proteins and to bind DNA in a sequence- specific manner to 
particular canonical sites know as an E-box (CANNTG). This DNA 
motif is present in the promoter of many muscle specific genes and 
is able to mediated the activation of genes in a MRF dependent 
manner. 
Myf 5 and MyoD are myogenic determinator factors contributing to 
myoblasts specification, while myogenin and MRF4 are myogenic 
differentiation factors contributing to the induction of terminal 
differentiation. 
Recently it was observed that in the mouse embryo Myf 5 is the 
first MRF to be expressed (E8.0). Myogenin is expressed after 
Myf5 (E8.5) and MRF4 at E9.0; MyoD is the last to be expressed in 
the somite at E10.5 (Francetic et al., 2011). 
Myoblast determination protein (MyoD) is believed to determine 
the differentiation potential of an activated myoblast, and acts 
together with myogenin and myocyte enhancer factor 2 (MEF2) to 
drive differentiation. It is known that Myf5 and MyoD are critical 
for myoblasts determination, while myogenin is a transcription 
factor that plays an essential role during muscle differentiation. 
Double mutants for MyoD and Myf5 are not able to form skeletal 
muscle because the muscle precursor population is absent (Rudnicki 
et al., 1993). In absence of these factors the cells in the somite, 
which would normally become myoblast, are not able to correctly 
locate in the site of myogenesis and then adopt a  different cell fate. 
In addition to activating skeletal muscle-specific gene, MyoD 
expression can also lead to cell cycle arrest. The importance of 
MyoD as an inhibitor of cell cycle progression can also be seen 
during muscle repair. One potential mechanism by which MyoD 
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can arrest cell cycle progression is through the transcriptional 
activity on the CIP1 gene, which encodes the cyclin-dependent 
kinase-inhibitory protein p21.  
Obviously these transcription factors do not act alone, but a part of 
complex signaling cascades that control every stage of myogenesis 
exists. 
The expression of MRFs is regulated by Pax3 and Pax7 (paired box 
protein 3 and 7). The paired box (PAX) transcription factor family 
is encoded by development control genes and it is characterized  by 
a highly conserved DNA-binding domain (PD). Pax3+/Pax7-  
positive muscle progenitor cells are located in the dermomyotome; 
these cells enter the myotome, the first skeletal muscle to form, in 
the central compartment of the somite, as the dermomyotome 
disaggregates, from embryonic day 10.5 (E10.5) in the mouse 
embryo.    
Pax3 is involved in the development of both epaxial and hypaxial 
muscle and it has a role in the survival of muscle precursors in 
hypaxial dermomyotome. Pax3 contributes also to regulate MRF, 
indeed Pax3 regulates Myf5 expression indirectly through the 
epaxial enhancer (DMRT2). In C2C12  myoblasts cells Pax3 
directly regulates expression of MyoD. 
Pax 7, indeed, is required for maintenance of adult satellite cells. 
In the Pax3/Pax7 double mutant mice, which are  lacking in both 
Pax3 and Pax7, only the primary myotome and its derivatives are 
formed, thus compromising all the subsequent stages of 
myogenesis. It is therefore proposed that all cells of the myogenic 
lineage should arise from Pax3/Pax7 positive population (Messina 
et al., 2009). 
Moreover it appears that Pax3 and Pax7 have partially overlapping 
and unique functions in myogenic progenitors. Both the pair- box 
genes are down regulated during myogenic differentiation, 
following differentiation of myogenic regulator factors. 
In Pax7-/- mice, adult myogenesis and regeneration are severely 
compromised whereas is not in fetal myogenesis. Based on these 
results Hutcheson and colleagues suggested that during foetal 
myogenesis the function of Pax7 is not essential and its activity 
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could be  compensated by other proteins, and the candidate is its 
paralogue Pax3. 
In summary Pax3 would be essential for embryonic myogenesis and 
Pax7 for adult myogenesis, while during the fetal myogenesis both 
genes should show redundant functions (Messina and Cossu, 2007). 
 
 
1.3 CDK9 PROTEIN 
 
Cyclin- dependent kinase 9 (CDK9) is a cdc-2 like serine/threonine  
kinase. The cyclin-dependent kinases (CDKs) take their name from 
a catalytic dependence on the cyclin family of regulatory proteins.  
Cdks are involved in cell cycle control and/or regulation of 
transcription. Their activity is coordinated by association with 
specific type of cyclins: this association forms a heterodimer, in 
which the cdk function as catalytic domain, whereas the cyclin 
function as regulatory subunits. The majority of cdks are involved 
in the control of cell cycle progression, only for CDK9 and CDK8   
the main function is the regulation of transcription via 
phosphorylation of RNA polII carboxyl terminal domain. 
 
 
 
Fig. 3 :  List of CDKs and cyclin partners (Romano et al., 2008) 
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The cellular function of CDK9 has been unknown until 1997, when 
Zue and colleagues identified in Drosophila CDk9 as a small 
subunit of the positive transcription and elongation factor (p-TEFb). 
CDK9 was initially named PITALRE. 
CDK9 is distributed in all type of human and murine tissue with 
high levels of expression in terminally differentiate cells.  
The regulatory units of CDK9 are the  T family cyclins (T1, T2a 
and T2b) and K. In Hela nuclear extracts CDK9 complexes with 
cyclin T1 for 80%, and for 10% with cyclin T2. The chaperone 
proteins HSP70, HSP90, and Cdc37 bind transiently and, therefore, 
stabilize the monomeric CDK9 preceding the association with one 
of its cyclin partners. 
 
 
 
Fig. 4: The CDK9/cyclin T1 complex. (Romano, 2013) 
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The elevated levels of CDK9 and its regulatory subunits in 
terminally differentiated cells, together with the fact that 
CDK9/cyclinT complexes are not cell cycle regulated, distinguish 
CDK9 from the other cdks. CDK9, at difference with other cdks 
that regulate cell cycle progression and phoshorylate histone H1, 
fails to phosphorylate H1. 
Together with cyclin T, CDK9 forms the positive transcription 
elongation factor b (P-TEFb), which allows transcriptional 
elongation through phosphorylation of the carboxyl-terminal 
domain  (CTD) of  the RNA polymerase II.  
The CDK9-related pathway regulates a wide range of functions in 
mammalian cell biology and replication program of numerous viral 
agents, such as immunodeficienty virus type I (HIV-1) and HIV2, 
human cytomegalovirus, herpes simplex virus 1, human adenovirus. 
Moreover, dysfunctions in the CDK9-related pathway are related 
with several forms of human tumors and cardiac hypertrophy. 
In structural studies CDK9 shows a typical kinase fold, comprising 
the N-terminal lobe (residue 16-108), which consist mainly of a bet-
sheet with one alpha-helix and a C terminal lobe (residue 109-230). 
The protein contains a phosporylated T loop structure (amino acids 
168-97), that is conserved among CDK protein and control access 
of ATP and substrate to the enzyme.   
In mammalian cells CDK9 is present in two isoforms: CDk9-42 and 
CDK9-55. CDK9-42 is a 42 kDa protein that is ubiquitously 
expressed and autophosphorylates itself. CDK9-55 originates from 
a promoter upstream of the 42k promoter and  presents 117 
additional  amino acids in the portion amino terminal, which is 
fused in frame with CDK9-42 sequence. The 13KDa in addition to 
CDK9-55 contain a region rich in praline and a region rich in 
glycine. The messengers of CDK9-42 are  transcribed from the 
promoter rich in  G/C but TATA less (Liu and Rice, 2000), while 
the messengers of CDK9-55 originate from the promoter containing 
the TATA sequence and placed approximately 500bp upstream 
(Shore et al., 2003). 
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Fig. 5: A) P55 and P42 indicate the start of transcription for the Cdk9-42 and 
CDK9-55. B) Representation of CDK9 molecular organization (Shore et al., 
2005). 
 
In Hela cells, CDK9-55 is present at approximately 10-20% of the 
level of CDK9-42. 
Both CDK9 isoforms generate heterodimers with cyclin T1,T2 and 
K, and they regulate the transcription via phosphorylation in the 
portion N-terminal of RNA polymerase II and their kinase activity 
is inhibited by 5,6- dichloro- l-b-D-ribofuranosylbenzimidazole 
(DRB). 
Two CDK9 isoforms present a different cellular distribution, 
CDK9-42 is localized in nucleus and in cytoplasm, whereas CDK9-
55 is essentially localized in cell nucleus. A different distribution of 
two isoforms it was observed in different type of human and mouse 
tissue: CDK9-42 is predominantly expressed in testis and spleen,  
whereas CDK9-55 is expressed in lung, liver and brain tissue. 
A differential expression of two CDK9 isoforms is also observed in 
various human and mouse cell culture system. For example CDK9-
42 is expressed in human cervical carcinoma Hela cells and in 
primary undifferentiated monocytes. CDK9-55 become 
predominant upon induced differentiation of human primary 
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monocytes into macrophages. Rat hepatocytes is expressed CDK9-
55, but in primary cell cultures there is an increase of CDK9-42. 
These findings indicate that two CDK9 isoforms expression is 
regulated in a cell type-specific fashion and in a signal-dependent 
manner. 
 
 
1.4 ROLE OF CDK9 IN SKELETAL MUSCLE 
 
Biressi and colleagues demonstrated that  CDK9 in association with 
cyclin T2a plays an important role during myogenic program. In the 
same study it was also demonstrated that CDK9 and its partners 
cyclin T2a isn’t down regulated during the formation of myotubes, 
but rather their activation is required for MyoD activation. The 
formation of multimeric complex containing CDK9, cyclin T2a and 
MyoD is detectable in cells during differentiation program, and the 
portion N-terminal of CDK9 interacts directly with bHLH region of 
MyoD, thus allowing the formation of a complex containing also 
cyclin T2a. As a result of muscle differentiation, the complex 
CDK9/cyclin T2 promotes the MyoD dependent transcription and 
accelerates the myogenic program. 
The main mechanism by which chromatin bound by CDK9/cyclin 
T2a complex activates the MyoD specific transcription is through 
the phosphorylation of the RNA polymerase II CTD by promoting 
the elongation (Hyacinths et al.,2006). 
CDK9 binds directly to MyoD in vitro (Simone et al., 2002), and 
takes part in the formation of multimeric complex  containing 
MyoD, cyclin T2a, p300, PCAF and BrgI in muscle cells (Giacinti 
et al., 2006). This transcriptional complex binds to the regulatory 
region of muscle specific genes to induce the acetylation of lysines 
on histones H3 and H4, the chromatin remodeling and the 
phosphorylation  of specific  serine targets for CDK9 at the level of 
RNA polymerase II CTD, thus promoting the gene expression 
(Simone and Giordano, 2007). 
Giacinti and colleagues analyzed the expression of two CDK9 
isoforms during differentiation of C2C12 cells, that are an 
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established cell line originate from mouse satellite cells. The 
reported results demonstrated that the expression levels of CDK9-
42 displayed similar levels between proliferative and differentiative 
phase,  while the expression of CDK9-55 isoforms increased during 
cells induced to differentiate. In the same study it was also observed 
that Cdk9-55 is induced during the regeneration program of damage 
fibers. 
 
 
1.5 THE CYCLINS PARTNERS OF CDK9 
 
Cyclins, a family of protein named for their cyclical expression and 
degradation, play an important role in the cell-division cycle. They 
act as a catalytic domain for CDK family protein: interaction 
between CDKs and cyclins occurs at specific stages of the cell 
cycle, and their activities are required for the progression of cell 
cycle.  
The core form of P-TEFb is a heterodimer between the CDK9 and 
its regulatory subunit cyclin T1 or the minor forms T2 or K. These 
complexes have been implicated in stimulating elongation upon 
initiation, of otherwise paused transcripts, by phosphorylating the 
C-terminal domain of RNA polymerase II. 
 
 
Fig. 6: Cyclin partners of CDK9: Cyclin K, cyclin T1 and  Cyclin T2a. 
PHE: phenylalanine. (Romano, 2013) 
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Cyclin T1 and T2 are expressed widely in human adult tissues with 
high levels in muscle, the spleen, thymus, testes, ovaries and in 
peripheral blood lymphocytes.  Cyclin K is expressed in adult 
mouse and in human tissue, but it most abundant in developing 
germ cells of the adult testes and ovaries. 
Between all cyclins partners of CDK9 only the complex 
CDK9/cyclin T1 can interact with the HIV transcriptional activator, 
Tat, to promote HIV replication and only CDK9/cyclin T2a can 
bind to MyoD to promote myogenic transcription. 
The cyclin T2 has two forms T2a and T2b, that derive from splice 
variants of the same transcript. These two cyclins share the first 642 
amino acids in common, but cyclin T2b contains in addition a large 
C terminal domain (CTD). 
The domain N-terminal of cyclin T1 contains a coiled coil motif, a 
His-rich motif and a PEST sequence carboxyl terminal. C-terminal 
PEST sequences are commonly found in G1 cyclins and serve to 
regulate protein turnover by the cellular ubiquitination. 
The cyclin homology box, formed by 290 amino acids, is the most 
conserved region among different members of the cyclin-family and 
serves to bind CDK9. The region of cyclin T1 from amino acids 1-
188 is necessary to interact with CDK9 in vivo. 
Peng and colleagues observed that removing the carboxyl terminal 
domain of cyclin T1 and T2 the ability of CDK9/cyclin T to 
phosphorylate the CTD of RNA polII and function in transcription 
was significantly reduced. 
The protein T2a shows high level of expression in human adult 
skeletal muscle cells and study in vitro suggest that CDK9/cyclin 
T2a complex might promote myogenic differentiation eliciting the 
expression of muscle-specific genes. 
The function of CDK9/cyclin K has been less clear. Cyclin K 
interacts with CDK9 in vitro and in vivo, and the CDK9/cyclin K 
complex can activate transcription only when tethered to RNA but 
not DNA. Cyclin K expression is also activated transcriptonally by 
the p53 tumor suppressor in response to DNA damage by 
adriamycin, ultraviolet (UV) light and ionizing radiation. 
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In addition to CDK9, cyclin K associates with CDK12 and CDK13: 
these heterodimers are both implicated in the control of RNA-pol II-
mediated transcription. 
 
 
1.6 7SKsnRNA and HEXIM1: THEIR ROLE IN REGULATING 
TRANSCRIPTION 
 
The positive transcription elongation factor b (P-TEFb) plays an 
important role in elongation of nascent RNA molecules by RNA 
polymerase II. 
In Hela cells there are two distinct P-TEFb complexes, which differ 
in size, composition and activity. A smaller P-TEF b complex has 
kinase activity and is composed of CDK9-42 or CDK9-55 and a 
cyclin partner T1,T2 or K. A large P-TEFb complex with reduced 
kinase activity composed by 7SKsnRNA and HEXIM1, in addition 
to CDK9 and cyclin T1, T2 or K. Independently 7SKsnRNA and 
HEXIM1 have limited inhibitory effects in P-TEFb complex, but 
together they inhibits the P-TEFb kinase activity. HEXIM1 is 
composed by two regions, the region comprised between amino 
acids 152-155 is involved in binding of 7SK, and a second region, 
amino acids 202-205 is involved in interaction with P-TEFb. Hexim 
1 was first identified from vascular smooth muscle cells treated with 
hexamethylene bisacetamide (HMBA), a proliferation-inhibiting 
and differentiation-inducing compound. Treatment  of HMBA led 
to increase in both mRNA and protein levels of HEXIM1. 
The N-terminal portion of Hexim1 was identified as inhibitory 
domain, a model proposed that upon binding to 7SKsnRNA, 
Hexim1 undergoes a  conformational change, thereby exposing its 
C-terminal domain for binding to CDK9/cyclinT1. 
Once binding to Hexim1/7SKsnRNA complexes, the kinase activity 
of p-TEFb is inhibited. About 50% of P-TEFb is found to associate 
with Hexim1 in cells, suggesting the importance of Hexim1 in the 
regulation of P-TEFb. 
 In cells there is a delicate and dynamic balance of the two P-TEFb 
complexes in cells. The dissociation of P-TEFb from 7SK and 
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HEXIM1 is rapid and reversible. Treatment of cells with UV 
irradiation, actinomycin D or DRB results in the dissociation of 
large P-TEFb complexes, and when cells are allowed to recover 
from those treatments, large P-TEFb complexes reform. 
Physiological signals leading to cardiac hypertrophy converge on 
activation of P-TEFb, through dissociation of 7SK, resulting in 
increased transcription and an increase in size of cardiomyocytes. 
 
 
 
Fig.7: Regulation of Hexim1: the conformational change of Hexim1 in C terminal 
portion and the binding with 7SKsnRNA and CDK9/Cyclin T1 (Dey et al., 2007). 
 
It was observed that phosphorylation of the T-loop of CDK9 has 
been implicated in the activation of P-TEFb, and is required for the 
formation of the 7SK/HEXIM1/P-TEFb complex. 
CDK9 acetylation, indeed, did not affect the association of P-TEFb 
with Hexim1 or 7SKsnRNA.  
Recently it was demonstrated that the skeletal muscle regeneration, 
which is achieved by a formation of new myofibers from the 
satellite cell pool, is controlled by the HEXIM1/P-TEFb pathway, 
that regulates satellite expansion after injury.  
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2. AIMS OF THE RESEARCH PROJECT 
 
This research project has analyzed and characterized the molecular 
and cellular mechanisms during development of the skeletal  
muscle, in particular investigating the involvement of the protein 
serine kinase  CDK9.  In the last years, my research group 
demonstrated that the CDK9 kinase protein, in association with the 
cyclin T2a, has an important role during the activation of the 
myogenic program (Giacinti et al., 2006). The complex 
Cdk9/Cyclin T2a isn’t down regulated  during myogenis, but its 
activation contributes to the transcriptional activity mediated by 
MyoD during the differentiation (Simone et al., 2002; Giacinti et 
al., 2006). In myoblasts,  induced to differentiate, CDK9 complexes 
with Myod and Cyclin T2a, is recluted on the promoter of specific 
muscle genes and promotes the phosphorylation of CTD of RNA 
polII (Giacinti et al., 2006).   
Recently the identification of new CDK9 isoform, CDK9-55 (Shore 
et al., 2003), and its expression in different tissues and cells, led us 
to analyze its role during myogenesis. It was demonstrated that the 
expression of CDK9-55 isoform increases during differentiation 
both in muscle stable lines and in myoblasts derived from primary 
cultures (Giacinti et al., 2006), allowed us to hypothesize the role of 
this isoform during myogenic program. The same research group 
analyzed the role of CDK9-55 isoform in damaged fibers and the 
obtained data demonstrated that CDK9-55 is highly expressed 
during regeneration process, while the CDK9-42 is not involved in 
this process (Giacinti et al 2008).  
Later on they start to investigate the role of two isoforms of CDK9 
during the differentiation process in   myogenesis both in vivo and 
in vitro. Preliminary results show that CDK9-42 and CDK9-55 have 
a different timing expression during development (between 
embryonic and fetal periods) (Background). 
The aim of this project is to get inside the specific mechanisms by 
which the two isoforms of cdk9 participate in the muscle 
differentiative mechanisms both in vitro and in vivo. 
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To this purpose we will further analyze the mechanisms by which 
the two isoforms are activated during myogenesis looking at the co-
expression of cdk9 activators (as different members of cyclin 
family)  and inhibitors (as 7SKsnRNA and Hexim1) at different 
stages of development. The same study will be performed on 
embrynal and fetal myoblasts in vitro. 
This innovative study try to discern among multiple possible 
combinations of cdk9 isoforms and activators/inhibitors so that to 
individuate the selective combination in correlation with a specific 
function during the different steps of myogenesis.  
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3. RESULTS AND DISCUSSIONS 
 
 
Background 
 
3.1 ANALYSIS OF CDK9-42 AND CDK9-55 EXPRESSION 
AND THEIR RELATIONSHIP WITH PAX3/7 AND MRFs 
DURING LIMB DEVELOPMENT 
 
Skeletal muscle differentiation is a multistep process in which 
muscle precursor cells initially express early differentiation 
markers, exit the cell cycle, then express muscle-specific structural 
genes and fuse to form multinucleated myotubes (Andrès and 
Walsh, 1996). 
In precedent works it was demonstrated the importance of CDK9 
during myogenic program, and it was demonstrated that the proteic 
levels of CDK9-42 are stable while the expression of CDK9-55 
increases during differentiation  both in C2C12 cells, an established 
cell line originated from mouse satellite cells, that in myoblast 
derived from primary coltures in vitro (Giacinti et al., 2008). 
Starting from this data the impact of CDK9 on myogenesis was 
characterized, the two isoform expressions were set up during 
muscle development. Western blotting analysis on total proteic 
extracts of limbs at different time of development  E10,5, E11,5, 
E12,5, E14,5, E16,5, E17,5, shows a different expression between 
two isoforms (Figure 1). 
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Figure 8: Western blotting analysis in mouse embryo limbs since E10.5 to E17.5 
of the marker of myogenic lineage, Pax3 and Pax7, and some MRFs, MyoD and 
Myogenin, and other genes involved in muscle differentiation in order to better 
characterize the impact of two CDK9 isoforms on the myogenic program during 
limb development. 
CDK9-55 
CDK9-42 
 Pax3 
Pax7 
MyoD 
Myogenin 
MHC tot 
Fast-MHC 
Slow-MHC 
Desmin 
β-actine 
Embryonic-MHC 
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Western blotting analysis shows that there is an inverse correlation 
between  two isoforms: CDK9-42  decreases, whereas CDK9-55 
increases during development. In particular at the time E14,5, the 
transition stage between the embryonic and fetal development 
phases, there is a switch in CDK9-42 and CDK9-55 expression, 
supporting the hypothesis that the two isoforms have different roles 
during myogenesis. CDK9-55 expression comes before the presence 
of  terminal markers of muscle differentiation, as myosin and its 
isoforms.  
It has been reported that embryonic MHC and slow MHCIβ 
isoforms are expressed during early myoblast differentiation, 
whereas the fast isoforms (MHCIIa, MHCIIx, MHCIIb) are up 
regulated later in differentiation. The transition between the slow 
and fast isoforms coincides with myotube hypertrophy; thus, the 
different expression of MHC isoforms defines a specific phase and 
phenotype during muscle development (Brown et al., 2011). 
From the analysis of the proteic extract it was observed a maximum 
of slow and fast MHC isoform expressions, which followed a bell 
trend between the late phase of embryonic development (E12,5) and 
the first steps of fetal myogenesis (E16,5), although fast MHC  was 
already expressed at  E10,5. 
In order to characterize the role of CDK9-55 and CDK9-42 on the 
myogenic program the determinators of myogenic lineage are 
analyzed, Pax3 and Pax7, and some MRFs, as MyoD and 
myogenin. Pax3 is the only one between all factors analyzed to 
anticipate the expression  of CDK9-55, showing  an oscillatory 
profile which determines the terminal differentiation. To allow for 
terminal differentiation it is necessary that Pax3 is down regulated 
in response to a co-expression of the primary MRF, MyoD (Relaix 
et al., 2005). Pax7 shows a different expression level, that increases 
gradually during fetal myogenesis. Pax7 seems to be required to 
allow the secondary myogenesis and its increase coincides with the 
satellite cell formation, during the time E16,5-E17,5. 
Later the CDK9 expression profile was correlated with MRFs: 
Western blotting analysis for MyoD confirmed an initial expression 
at E11.5, followed by an increase at E12.5 up to steady levels at the 
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late stages of limb development (E16.5-E17.5). Worthy of attention 
was the transient decrease at stage E14,5 dpc, this decrease 
coincides with the peak in expression of the myosin heavy chains 
and with their “bell” progress. The initial expression of MyoD is 
enough to activate the myogenic program, then its down regulation 
is necessary for terminal differentiation and to allow for the 
expression of sarcomere filaments (Choi et al., 1990). Furthermore 
the expression of MyoD followed a pattern similar to that of CDK9-
55, suggesting a correlation between MyoD and CDK9-55. For 
Myogenin, MRF involved in the late differentiation of muscle cells 
and is activated following the expression of MyoD and Myf5 to 
promote the formation of myocites and myotubes, it was observed a 
progressive increase from E12.5, with a performance similar to 
MyoD, although Myogenin showed a particular increase at  stage 
E17.5. 
Desmin protein levels were not detected at early stages of limb 
development (since E10.5 to E14.5), whereas its expression levels 
were higher during fetal myogenesis (E16.5-E17.5). The Desmin 
maximum at E17.5 coincides with the Pax7 maximum, according to 
the fact that they are two important markers of satellite cells, highly 
expressed at this development phase. 
The molecular characterization of two CDK9 isoforms during 
myogenic program, the genic expression, was analyzed by qRT-
PCR. Embryonic limbs at E10.5 were used as a control, and mRNA 
levels were normalized to the housekeeping GAPDH. The obtained 
results (Fig. 9, B.) showed that CDK9-55 was significantly up-
regulated throughout muscle differentiation, peaking in fetal limbs 
(E14.5-E17.5), whereas CDK9-42 displayed a progressive decrease 
in its expression levels during development (Fig. 9, A). 
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Figure 9: A)mRNA levels of CDK9-42  in mouse embryo limbs from embryonic 
day (E10.5) to fetal day (E17.5). 
 * E10,5 limbs (ctr) vs E14,5 limbs P <0,05 
* E10,5 limbs (ctr) vs E17,5 limbs P <0,05 
B)mRNA levels of CDK9-55  in mouse embryo limbs from embryonic day (E10.5) 
to fetal day (E17.5). 
* E10,5 limbs (ctr) vs E12 limbs P <0,05  
* E10,5 limbs (ctr) vs E17 limbs P<0,05 
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4. RESULTS AND DISCUSSIONS 
 
4. 1 ANALYSIS OF THE CDK9 REGULATOR DURING 
MUSCLE DEVELOPMENT 
 
4.1. 1 CYCLINS T1, T2a AND K EXPRESSION  
 
The different functions of CDK9 on distinct promoters depend on 
their ability to associate with different regulatory subunits. 
In adult tissues the members of Cyclins T family are the first 
regulators of CDK9 kinase activity. The interaction between Cyclin 
T and CDK9 is necessary to control the transcription of muscle 
specific genes. It is known that the complex CDK9/CycT2a 
increases the transcriptional activity of MyoD and promotes 
myogenic differentiation (Simone et al., 2002). 
Therefore, in mouse embryonic and fetal limbs RNA extracts the 
expression of canonical CDK9 partners, cyclins T (T1 and T2a) and 
K, are examined. 
qRT-PCR results showed that cyclins T1 and T2a were clearly 
expressed at E11,5 and at E12,5 stages, suggesting their major 
involvement in embryonic myogenesis rather than in fetal 
myogenesis, although a partial recovery of cyclin T1 expression 
was obtained at stage E16.5 (Fig. 10). 
As for cyclin K, a maximum of its expression was observed at 
E16,5, whereas it was poorly expressed during embryonic 
development (from E10,5 to E12,5).  Cyclin K was significantly up-
regulated during fetal myogenesis, therefore we supposed its 
involvement in this process in association with CDK9-55, that is 
mainly involved in muscle differentiation.  
Conversely, cyclin T1 and T2a were expressed in concomitance 
with CDK9-42 expression, suggesting their preferential association 
with this CDK9 isoform.  
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Figure 10: mRNA levels of Cyclin T1 (A), T2a (B) and K (C) in mouse embryo 
limbs from  E10,5 to E17,5. Cyclin T1 and T2a are mainly expressed during 
embryonic myogenesis, whereas cyclin K is significantly up-regulated during 
fetal myogenesis. 
A)** E10,5 limbs (ctr) vs E11,5 limbs P<0,005 
 ** E10,5 limbs (ctr) vs E12,5 limbs P< 0,005 
*E10,5 limbs (ctr) vs E14,5 limbs P<0,05 
*E10,5 limbs (ctr) vs E16,5 limbs P< 0,05 
B)***E10,5 limbs (ctr) vs E12,5 limbs P<0,0005 
*** E10,5 limbs (ctr) vs E16,5 limbs P<0,0005 
*E10,5 limbs (ctr) vs E17,5 limbs P <0,05 
C) **E10,5 limbs (ctr) vs E14,5 limbs P <0,005 
 
 
 
qRT-PCR  results were confirmed by Western Blotting analysis of 
embryonic and fetal limb protein extracts. 
For Cyclin T1 a marked expression was observed at early stages of 
limb development (E11,5-E12,5), whereas it was not detected 
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during the late phase (from E14,5 to E17,5) (Fig. 11). It isn’t 
possible to analyze  the cyclin T2a by Western blotting due to the 
absence of a  good antibody. 
Conversely, cyclin K was clearly expressed from E16,5, confirming 
its main function during secondary myogenesis, which is 
characterized by cell cycle withdrawal and terminal differentiation. 
It is well known in literature that the induction of differentiation in 
cultured myoblasts results in up-regulation of cell cycle inhibitors 
such as p21 and p16 ( Guo et al., 1995; Schneider et al., 1994). 
Indeed p21 is expressed when the differentiation process is ongoing  
and in concomitance with cyclin K, at stage E16,5 and E17,5, 
supporting the correlation between p21 induction and cell cycle 
arrest of muscle progenitors, thus inducing differentiation. 
 
 
 
 
 
Figure 11: Western blotting analysis showing cyclins T1, K and p21, normalized 
with tubuline, in mouse embryo limbs from E11,5 to E17,5. 
 
 
This data obtained with RT-PCR and Western blotting analysis 
allowed us to hypothesize an association of cyclin T with CDK9-42 
and cyclin K with CDK9-55. 
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4.1.2 CYCLINS D3, H AND L IN VIVO ANALISYS 
 
Cyclin D3 is expressed at very low levels in myoblasts due to 
GSK3β-mediated phosphorylation and consequent degradation, 
which is prevented in differentiating cells, where pRb stabilizes 
cyclin D3 by directly binding to it, thus allowing up-regulation of 
cyclin D3 during myogenesis (De Santa et al., 2007). 
The qRT-PCR analysis showed low expression levels of cyclin D3 
in primary myogenesis (from E10,5 to E 12,5), whereas it became 
up-regulated during secondary myogenesis (from E14,5 to E 17,5), 
suggesting its involvement  in  the induction and/or establishment of 
skeletal muscle differentiation, according to scientific reports. 
 
                                             
 
 
 
Figure 12: mRNA levels of Cyclin D3 in mouse embryo limbs from E10,5 to 
E17,5. Cyclin D3 is up-regulated during fetal limb development (from E 14,5 to 
E17,5). 
 * E10,5 limbs (ctr) vs E17,5 limbs P< 0,05 
 
In scientific articles it is reported that cyclin H, complexed with 
CDK7, has a role in transcriptional regulation mediated by its 
phosphorylation of specific sites  on RNA polymerase II, so we 
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investigated the expression of cyclin H during embrional and fetal 
myogenesis. 
The data obtained by RT-PCR analysis demonstrated that there isn’t 
an important difference of expression between two myogenesis. It is 
possible to observe that the expression levels of cyclin H  are stable 
enough during primary myogenesis, while for secondary 
myogenesis it was observed a decrease of expression at the time 
E17,5, when there is cell cycle arrest. 
 
  
                                                                                    
 
Figure 13: mRNA levels of cyclin H in mouse embryo limbs from E10,5 to E17,5. 
The expression levels of cyclin H are stable for primary myogenesis (from E10,5 
to E12,5), while during secondary myogenesis there is a decrease at the time 
E17,5. 
 * E10,5 limbs (ctr) vs E14,5 limbs P <0,05 
** E10,5 limbs (ctr) vs E16,5 limbs P<0,005  
** E10,5 limbs (ctr) vs E17,5 limbs P<0,005 
 
Precedent works demonstrated that CDK-11, a kinase that as CDK9 
regulates the transcription through the phosphorylation of CTD of 
RNA polII, complex with cyclin L, this complex is involved in 
splicing. 
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In this experiment the expression of cyclin L was tested, and we 
observed that this cyclin isn’t involved in the muscle development, 
indeed it is expressed weakly only at the time E12,5, during primary 
myogenesis, while during fetal myogenesis it decreases rapidly, 
above all at time E17,5. 
 
 
 
 
                                                                                                       
 
                                                                                                                                         
Figure 14: mRNA levels of cyclin L in mouse embryo from E10,5 to E17,5. 
*** E10,5 limbs (ctr) vs E16,5 limbs P<0,0005 
**E10,5 limbs (ctr) vs E17,5 limbs P <0,005 
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4.2 ISOLATION OF MYOBLASTS AT DIFFERENT TIMEs OF  
DEVELOPMENT 
 
Precedent works demonstrated that development of the embryo is 
coordinated by sequential and different responsiveness to external 
signals. When embrional and fetal myoblasts are planted they 
present different characteristics. Embrional myoblasts are elongated 
cells that differentiate in multinucleated myotube, while fetal 
myoblasts show triangular shapes, proliferate more and differentiate 
in multinucleated myotubes (Biressi et al., 2007). Studies on 
primary cultures allow us to discriminate the intrinsic properties of 
the population of myoblasts isolated from the draft of the limb. 
These cells were cultured and induced to differentiate for 3 and 5 
days. 
 
 
4.2.1 ANALYSIS OF CDK9 ISOFORMS EXPRESSION IN 
VITRO 
 
Data obtained in vivo demonstrated that two CDK9 isoforms show 
an inverse correlation in genic expression levels and in transcript 
levels during muscle development. This different expression profile 
suggests a different role of two CDK9 isoforms: CDK9-42 seems to 
be involved during the early phase of muscle development, whereas 
CDK9-55 is required in the final phase of muscle formation. 
Preliminary study on stable cell line C2C12 demonstrated  that 
expression levels of CDK9-55 were increased during 
differentiation, whereas the CDK9-42 levels were stable. 
In order to characterize the specific role of two CDK9 isoforms on 
myogenesis and its relationship with the other factors involved in 
muscle formation , mouse embryonic (E12) and fetal (E16) CD1 
mice limb primary cultures were set up. Then the expression in vitro 
of CDK9-42 and CDK9-55 were analyzed. 
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Figure 15: mRNA levels of CDK9-42 (A) and CDK9-55 (B) in mouse embryonic 
(E12) and fetal (E16) limb primary cultures. GM refers to proliferating 
myoblasts, while 3d to differentiating myoblasts, harvested 3 days after the 
induction of differentiation. 
A)**E12 GM (ctr) vs E12 3d P<0,005 
** E16 GM (ctr) vs E16 3d P <0,005 
B) **E12 GM (ctr) vs E12 3d P <0,005 
* E16 GM (ctr) vs E16 3d P<0,05 
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The RT-PCR analysis demonstrated a significant increase of CDK9-
55 isoform in cells induced to differentiate both in embrional phase 
(E12) then in fetal phase (E16), whereas transcript levels of CDK9-
42 are stable. 
Also the analysis of Western blotting analysis (Fig.16) showed an 
increase of CDK9-55 during differentiation. 
 
 
Figure 16: Analysis of  Western blotting analysis on proteic extracts of 
embrional myoblasts (E12) and fetal myoblasts (E16) . 
 
 
This data supports the hypothesis that there is a specific activation 
for CDK9-55 isoform during the differentiation phase of muscle 
cell. 
Embrional and fetal cultures have, another, a different profile of 
differentiation, showing a different expression profile during the 
expression time of sarcomeric myosin. It was observed that  fetal 
myoblasts (isolated at the time E16,5) expressed sarcomeric 
filaments on the third day of differentiation (Fig. 16). 
The new antibody, pospho CDK9, that detects endogenous levels of 
CDK9 only when phosphorylated at Thr186, permitted to verify 
CDK9-42 
 MF-20 
CDK9-55 
Tubuline 
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which of the two CDK9 isoform is active during differentiation. 
Preliminary data obtained on proteic extract of embryonic 
myoblasts (E12) demonstrate that CDK9-55 is the active isoform 
during differentiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Western blotting analysis on embryonic myoblasts (E12) in 
proliferation and differentiation  phase, using the phospho CDK9 antibody, that 
permits the active isoform  to be verified during differentiation. 
 
 
4.2.2 CYCLINS T1, T2a AND K  
 
In mouse embryonic and fetal limbs  RNA were extracted and  the 
expression of canonical CDK9 partner was analyzed. 
For cyclinT1 the results showed a progressive decrease of its 
expression levels in differentiating myoblasts (E12 3d and 5d); a 
similar trend was observed also in fetal myoblasts (E17), although 
cyclin T1 was slightly up-regulated in 3d differentiating cells, 
suggesting its marginal involvement in myogenesis. 
 
     
 
p-CDK9-42 
    MF-20 
CDK9-55 
CDK9-42 
pCDK9-55 
Tubuline 
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Figure 18: mRNA levels of cyclin T1 in mouse embryonic E12 (A) and fetal E17 
(B) limb primary cultures. Cyclin T1 expression levels decrease in differentiating 
embryonic and fetal myoblasts, although a  slight increase in E17 3d 
differentiating cells. 
A)*E12 GM (ctr) vs E12 3d P<0,05 
*** E12 GM (ctr) vs E12 5d P<0,0005 
B)* E17 GM (ctr) vs E17 3d P<0,05 
 
 
On the other hand, cyclin T2a was progressively over expressed in 
3d and 5d embryonic myoblasts, and only in 3d fetal myoblasts, in 
concomitance with the CDK9-55 expression. This supports the 
hypothesis  that cyclin T2a  in vitro might complex with CDK9-55, 
thus promoting myogenic differentiation and muscle specific gene 
expression. On the contrary, the fact that cyclin T1 does not 
significantly increase in both embryonic and fetal myoblasts 
induced to differentiate, may indicate a different role from 
differentiation.  
 
 
 
 
 
A B 
R
e
la
ti
v
e
 e
x
p
re
ss
io
n
 
R
e
la
ti
v
e
 e
x
p
re
ss
io
n
 
 40 
 
 
 
 
                                                                            
         
Figure 19: mRNA levels of cyclin T2a in mouse embryonic E12(A) and fetal 
E17(B) limb primary cultures. Cyclin T2a is progressively over expressed in 3d 
and 5d embryonic myoblasts, and only in 3d fetal myoblasts. 
A)***E12 GM (ctr) vs E12 3d P <0,0005 
***E12 GM (ctr) vs E12 5d P<0,0005 
B) * E17 GM (ctr) vs E17 3d P <0,05 
 
Cyclin k was shown to be the regulatory cyclin of CDK9 during the 
fetal myogenesis  in in vivo experiments carried out on developing 
limbs. 
In vitro this finding does not seem to occur, indeed the gene 
analysis revealed that cyclin K expression  decreases progressively 
in both embryonic than fetal myoblasts after 3 and 5 days of 
differentiation. 
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Figure 20: mRNA levels of cyclin K in mouse embryonic E12 (A) and fetal E17 
(B) limb primary cultures. Cyclin K undergoes a gradual decrease of its 
expression in embryonic and fetal myoblasts. 
A)**E12 GM (ctr) vs E12 3d P< 0,005 
*** E12 GM (ctr) vs E12 5d P< 0,0005 
B) ** E17 GM (ctr) vs E17 5d P <0,005 
 
Cyclin K, as well Cyclin T1, does not seem to be involved in the 
differentiation in vitro, while in vivo cyclin k was expressed during 
fetal myogenesis; whereas in vitro only for the cyclin T2a it was 
observed an increase of expression during the differentiation phase 
both for embrional and fetal myoblasts.  
 
 
4.2.3 CYCLIN D3, H AND L IN EMBRIONAL AND FETAL 
MYOBLASTS 
    
The obtained results in vivo showed that cyclin D3 is expressed 
during fetal myogenesis, supporting the hypothesis that it is 
involved in the induction of the muscle differentiation. In vitro 
cyclin D3 shows a different profile of expression, indeed our qRT-
PCR analysis showed steady expression level in embryonic 
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myoblasts (E12, 3d and 5d), whereas it was down regulated in 
differentiating fetal myoblasts (E17, 3d and 5d), suggesting its 
involvement only in embryonic myogenesis. 
 
 
 
 
         
 
 
                                                                                        
 
Figure 21: mRNA levels of cyclin D3 in mouse embryonic E12 (A) and fetal 
E17(B) limb primary cultures. Cyclin D3 shows steady expression levels in 
embryonic myoblasts, whereas it is down regulated in fetal myoblasts.  
A)* E12 GM (ctr) vs E12 5d P <0,05 
B)* E17 GM (ctr) vs E17 5d P <0,05 
 
In vivo we analyzed also cyclin H and L, and we didn’t observe 
significant profile of expression both in embrional and fetal 
myogenesis. Cyclin L is expressed, at low levels, during 
differentiation of embryonic myoblasts, indeed its expression 
increases progressively, while in fetal myoblasts its expression 
decreases gradually during differentiation. 
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Figure 22: mRNA levels of Cyclin L in mouse embryonic E12 (A) and fetal E17 
(B) limb  primary cultures. 
A)*** E12 GM (ctr) vs E12 3d P <0,0005 
***E12 GM (ctr) vs E12 5d P <0,0005 
B)** E17 GM (ctr) E17 3d P <0,005 
 
 
 
For cyclin H we observed a profile of expression similar to cyclin 
L, also this cyclin increases during differentiation of embryonic 
myoblasts, while during differentiation of fetal myoblasts it 
decreases. 
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Figure 23: mRNA levels of cyclin H in mouse embryonic E12 (A) and fetal  E17 
(B) limb primary cultures. 
B)*** E17 GM (ctr) vs E17 3d P< 0,0005 
***E17 GM (ctr) vs E17 5d P<0,0005 
 
 
 
4.3 THE EXPRESSION OF 7SKsnRNA and HEXIM1 DURING 
DIFFERENTIATION  
 
In Hela cells there are two distinct P-TEFb complexes, which differ 
in size, composition and activity. The smaller P-TEFb complex has 
kinase activity and is composed of CDK9-42 or CDK9-55 and a 
cyclin partner T1,T2 and K. A large P-TEFb complex with reduced 
kinase activity was found to contain the small nuclear RNA 7SK 
and HEXIM1, in addition to P-TEFb subunit. There is a delicate 
and dynamic balance between the two P-TEFb complexes in the 
cells. The disassociation of P-TEFb from 7SKsnRNA and Hexim1 
is reversible. 
In order to  verify the modulation of CDK9 expression during 
muscle differentiation  of C2C12 cells the RNA 
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immunoprecipitation assays were done. In this assay, similar to 
chromatin immunoprecipitation (ChIP), cells are treated with 
formaldehyde to generate protein-protein, protein-DNA and protein-
RNA cross links between molecules. A whole-cells extract is 
prepared in the presence of RNase inhibitors to maintain the 
integrity of RNA, and the cross-linked nucleic acids are sheared by 
sonication to enable their solubilization. The extract is then 
enzymatically treated to remove DNA and the resulting material is 
immunoprecipitated with an antibody against the protein of interest. 
In the first step of this assay we analyzed the expression of 
7SKsnRNA on total extract during a proliferative phase and a 
differentiative phase of C2C12 cells; we observed that 7SKsnRNA 
is expressed in C2C12 cells only during proliferation, while it isn’t 
present in cells induced to differentiation. 
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Figure 24: mRNA levels of  7SKsnRNA in total extract of C2C12 cells during 
proliferative phase and differentiative phase. 
*** Input C2C12 Gm (ctr) vs Input C2C12 24h P<0,0005 
***Input C2C12 Gm (ctr) vs Input C2C12 48h P<0,0005 
***Input C2C12 Gm (ctr) vs Input C2C12 5d P<0,0005 
 
 
On total proteic extracts of C2C12 cells it was analyzed also the 
HEXIM 1 expression and it was observed that it presents a peak of 
expression after  5 days of differentiation, when there is the 
formation of myotubes.   
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     1      2       3       4 
  Hexim1 
  Tubuline 
 
 
 
Figure  25: Western blotting analysis on total extract of C2C12 cells to evaluate 
the expression of HEXIM1. 
 
By using RNA immunoprecipitation (RIP) it is possible to detect 
the association of individual proteins with specific RNA. 
In this experiment we isolated the RNA associated to CDK9 and 
then it was observed the expression of 7SKsnRNA. Data obtained 
with RT-PCR demonstrated that 7SKsnRNA is associated with 
CDK9 in the proliferative phase, but its expression decreases during 
differentiation. 
 
 
 
 
 
 
 
1. C2C12 GM 
2. C2C12 24h 
3. C2C12 3d 
4. C2C12 5d 
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Figure 26: mRNA levels of 7SKsnRNA associated to CDK9 in C2C12 cells 
during proliferative and differentiative phase. 
** RIP C2C12 GM (ctr) vs RIP C2C12 24h P< 0,005 
 
 
A different approach of expression for HEXIM1 it is possible to 
observe when it was immunoprecipitated with CDK9, therefore it is 
associated with CDK9 during the proliferative phase and in the 
early phase of differentiation, its expression decreases during 
advanced differentiation. 
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   1        2      3       4 
 Hexim1                              
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Figure 27: Western blotting analysis on extract after immunoprecipitation with 
CDK9 to verify the expression of Hexim1 associated with CDK9. 
 
 
 
4.4 THE ROLE OF TWO CDK9 ISOFORMS IN DENERVATED 
MUSCLE 
 
 Skeletal muscle is susceptible to injury after direct trauma and or 
indirect trauma, in order to maintain a  functional skeletal 
musculature this tissue has a notable ability to initiate the repair of 
the damage muscle. In fact, after muscle injury, a  complex set of 
cellular responses is activated, leading to the regeneration of a well-
innervated, totally vascularized and contractile muscle apparatus 
(Chargè et al., 2004). 
A precedent work demonstrated that the CDK9-55 is the isoform 
involved in regeneration of muscle after injury, our studies analyzed 
the expression of CDK9 isoforms in muscle after denervation, in 
order to evaluate the importance of CDK9- 55 in the innervation 
process. In scientific articles is known that in myogenesis the 
process of innervation occurs during fetal myogenesis, where we 
observed an increase of expression of CDK9-55, while the CDK9-
42 decreases. 
In our experiments we analyzed the expression of two isoforms in 
denervated muscle: we caused a trauma in sciatic nerve of mice and 
then tibial  and quadriceps were extracted after a week and a month 
by denervation.  
We analyzed the muscle exctracted after denervation at proteic 
level, by Western blotting analysis and the obtained data 
demonstrated that two isoforms are expressed more in denervated 
5. C2C12 GM 
6. C2C12 24h 
7. C2C12 3d 
8. C2C12 5d 
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muscle, with a peak of expression in quadriceps after a month of 
denervation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Western blotting analysis in tibial and quadriceps after a week and a 
month of denervation, to evaluate CDK9-55 and CDK9-42 expression. 
 
 
By using densitometry analysis we compared the expression of 
CDK9-55 and CDK9-42 and it was observed that CDK9-55 is the 
isoform expressed more in denervated muscle both in the tibial and 
quadriceps, after a week and a month of denervation.  
 
 
Ponceau 
CDK9-55 
CDK9-42 
1         2       3      4        5       6        7       8 
1. Th ctr 1 week 
2. Th den 1 week 
3. Th ctr 1 month 
4. Th den 1 month 
5. Ta ctr 1 week 
6. Ta den 1 week 
7. Ta ctr 1 month 
8. Ta den 1 month 
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Figure 29: Densitometry analysis comparing the two CDK9 isoform expressions 
in proteic exctract  in denervated muscle (tibial and quadriceps), after a month 
and a week of denervation. Protein levels of CDK9-42 and CDK9-55 were 
normalized respect to β-actine, which was used as a control. 
           
 
After denervation in muscle there is an increase of the transcription 
factors, above all there is an increase of myogenin, that induces an 
increase of transcription of genes as  an Ach receptor.  
In our experiments we found that CDK9-55 is the isoform 
expressed more in muscle after a month of denervation, and this 
phase is characterized by regeneration and innervation of the 
muscle, we hypothesize that this isoform is involved in the 
innervation process, in concomitance with an increase of expression 
of myogenin. 
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4.5 DISCUSSION 
 
Skeletal muscle is a highly complex and heterogeneous tissue 
serving a multitude of functions in the organism, in particular 
movement, postural behaviour and breathing. 
The process of generating muscle, myogenesis, can be divided into  
several distinct phases. During embryonic  myogenesis (E10,5-
E12,5), mesoderm derived structure generates the first fibers of the 
body, and during the subsequent fetal (E14,5-E17,5) and post natal 
development, additional fibers form along these template fibers 
(Parker et al., 2003). The continued growth of the muscle is due to a 
population of muscle progenitors, which co-express Pax3 and Pax7 
and can enter the myogenic program with the activation of the 
myogenic regulatory factors Myf5 and MyoD (Relaix et al., 2003). 
In the perinatal phase, muscle progenitors initially proliferate 
extensively but later on decrease as the number of myonuclei 
reaches a steady state and myofibriller protein synthesis peaks 
(Davis and Fiorotto, 2009). Once the muscle has matured, these 
myogenic precursors cells, known as satellite cells, maintain the 
tissue homeostasis. This type of myogenesis occurs in response to 
different types of stimuli, including direct trauma, further  growth 
demands on genetic defects (Huard et al., 2002), and it depends on 
the activation and differentiation on satellite cells in new fibers. 
The obtained data permitted  to conclude that the expression of 
CDK9 kinase is induced during differentiation of muscle cell in 
vitro, in culture of embryonic and fetal myoblasts,  and in vivo. 
Scientific articles reported that CDK9 binds directly MyoD in vitro 
(Simone et al., 2002) and takes part in the formation of multimeric 
complex cointaining MyoD, cyclin T2a, p300, PCAF and BrgI in 
muscle cells (Giacinti et al., 2006). This transcriptional complex 
binds to the  regulatory regions of muscle-specific genes to induce 
the acetylation of specific lysines on histones H3 and H4, the 
chromatin remodelling and the phosphorylation of serines target-
specific for CDK9 at the levels of the RNA polymerase II CTD and 
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promotes the gene transcription (Giacinti et al., 2006; Simone et al., 
2007). 
The identification of new CDK9 isoform, called CDK9-55 (Shore et 
al., 2003) and  its involvement in differentiated cells and tissues, led 
us to evaluate the role and  the possible impact of this isoform 
during myogenesis. 
In additions the results of Giacinti and colleagues demonstrated that 
CDK9-55 expression increases significantly during differentiation 
in stable muscle cell line (Giacinti et al., 2008); in the same study it 
was observed that CDK9-55 is highly expressed during regeneration 
process of damage myofibers. 
Subsequently the research group start to characterized the profile of 
expression of CDK9 isoforms during muscle development.  In this 
preliminary study the two CDK9 isoforms was analyzed during 
mouse embryogenesis starting at the stage E10,5 and they observed  
that there is a different correlation between two  CDK9 isoforms, 
both in protein extracts and at transcript levels, during muscle 
development. This study in vivo demonstrated that CDK9-55 
increases progressively during muscular differentiation, while 
CDK9-42 isoform decreases gradually. These data have suggested a 
different role of two isoforms. It is interesting to observe that at 
E14,5 dpc, key point of transition between embrional and fetal 
myogenesis, the CDK9-55 increases while CDK9-42 decreases. 
In order to characterize the role of CDK9 isoforms it was also tested 
the expression of some genes involved in myogenic program. 
The determiners of myogenic lineage, Pax3 and Pax7, play an 
important role in the formation and in maintenance of muscle tissue 
both during its development and after its formation. Both  genes are 
supposed to be involved in the myogenic cell specification and are 
known as early markers of the forming dermomyotome, which is 
the source of future myoblasts (Goulding et al., 1991). It is known 
that at E11,5 Pax3 positive cells in the somites constituted the 
dermomyotome and delaminating myotome, this data was 
confirmed also by Western blotting analysis, Pax3 is indeed 
expressed at the stage E10,5 and E11,5, then it must be down 
regulated, for a co-expression of MyoD (Relaix et al., 2005). This 
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phase was present at the stage E11,5 and E12,5 dpc, in 
concomitance we observed an increase of CDK9-55 isoform. 
Moreover, the presence of satellite cells in the late fetal phase of 
muscle development is confirmed by high levels, from E16,5 dpc to 
E17,5 dpc,  of both desmin, known marker of active satellite cells, 
and Pax7. 
The obtained data are in agreement with what is known in the 
scientific reports, indeed precedent works demonstrated that an 
expression profile Pax3+/Pax7- is characteristic of embryonic 
myoblasts, while a profile Pax3-/Pax7+ is characteristic of fetal 
myoblasts (Biressi et al., 2007). 
Muscle regulatory factors play a critical role in myogenesis, and 
their expression is tightly regulated, according their physiological 
functions. In this work we analyzed the expression of MyoD and 
Myogenin during muscle differentiation. In scientific articles is 
reported that MyoD is a marker of determined myoblasts, whereas 
myogenin-positive cells were judged as myoblasts that are more 
advanced in their differentiation. The results, according to the 
literature, have highlighted that the two protein are expressed at 
different stages of muscle development, being MyoD expressed 
during embryonic and  Myogenin during foetal myogenesis. 
The data obtained demonstrated that the more differentiation in 
muscle development is present between the stage  E14,5 and E17,5, 
this phase is characterized by an increase of muscular mass. This 
period coincides with the increase of CDK9-55 isoform expression, 
whereas the CDK9-42 expression decreases. 
By the Western blotting analysis we observed that the myosins 
expression started at the stage E14,5, time of switch of embrional 
and foetal myogenesis, but for the isoform fast of myosin we 
observed that was expressed at the time E10,5. This data permitted 
to suppose that the process, present at the stage E10,5, for the 
presence of the isoform fast of myosin, is the result of precendent 
inductive mechanisms present in somites. 
It is known that activation of MyoD is in turn depend on the 
CDK9/cyclin T2a complex, which plays a critical role in the 
activation of myogenic program (Giacinti et al., 2006). CDK9 has 
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been reported to participate to the differentiation program of several 
cell type, as monocytes, B and T-lymphocytes, mainly complexed 
to cyclin T1, suggesting that the CDK9/cyclin T1 complex may be 
specifically required for the differentiation process of T 
lymphocytes. 
In muscle differentiation, CDK9 binds to cyclin T2a, which is not 
down-regulated during myotube formation; rather their activity 
contributes to the activation of MyoD (Simone et al., 2002). In 
particular, the N-terminal region of CDK9 directly interacts with the 
bHLH region of MyoD, allowing the formation of multimeric 
complex also containing cyclin T2a (Giacinti et al., 2006; Simone et 
al., 2002).  It is detectable in muscle cells during the activation of 
differentiation program, when it can provide a functional link 
between MyoD and the basal transcription machinery. In fact, it 
binds to the chromatin of muscle specific gene regulatory regions, 
including the acetylation of histones H3 and H4 specific lysines, 
chromatin remodelling, stimulation of transcription elongation 
through the ability of CDK9 to phosphorylate target serines at the 
RNApolII CTD, and finally muscle-specific gene expression 
(Simone et al., 2006;  Giacinti et al., 2006; Simone and Giordano 
2007). 
The kinase activity of CDK9 is tightly regulated: association with a 
cyclin partner and phosphorlation of the T-loop is needed for 
activation of CDK9. 
Roughly 80% of the CDK9 is complexed with cyclinT1, 10% with 
cyclin T2a and 10% with cyclin K: each of the cyclin proteins 
complexed with CDK9, form an active P-TEFb molecule. This 
molecule is able to phosphorylate the carboxyl-terminal domain of 
RNA polymerase II (RNA polII).  
Recent study show that CDK9/cyclin T complex may be recruited 
to specific promoters by cellular transcription factors that bind to 
the promoter sequences of genes regulated at the level of 
transcriptional elongation (Simone and Giordano,2001). It has been 
shown also that CDK9/ cyclin T is a very stable complex, with a 
half-life of about 36h, while free CDK9 appears to be degraded 
rapidly, with a half-life of about 6h (Majello and Napolitano, 2001). 
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According to scientific articles, cyclins T1, T2a and K bind to 
CDK9, prompting us to investigate their involvement during 
myogenesis.  
In vivo results have shown a different expression of these CDK9 
cyclin partners along the two phases of myogenesis. Indeed cyclin 
T1 and cyclin T2 are expressed during primary myogenesis, while 
cyclin K is expressed during fetal myogenesis. We also observed a  
further correlation between two CDK9 isoforms and cyclins: cyclin 
T1 and  T2  are probably associated with CDK9-42, while cyclin K 
is associated with CDK9-55, that is expressed principally during 
fetal myogenesis. 
We observed also that the expression of  cyclin k coincides with the 
increase of expression of p21, an inhibitor of cellular cycle, that 
determines cellular arrest in concomitance with the cellular 
differentiative program. In a recent study it was demonstrated that 
CDK9 coordinates the transcription of p21, in collaboration with 
BRG1 (a factor of remodelling of cromatine) and STAT3 (Giraud et 
al., 2004). It is known that Cyclin K is a target of p53 and it is 
activated in response to a signal of cellular arrest, or in response to 
stress p53-mediated. The cyclin K complexed with CDK9 seems to 
be the specific P-TEFb activated for the transcription of genes 
induced by p53, as p21. It was also demonstrated that while the 
complex CDK9/Cyclin T1 induces the replication of HIV-1, the 
complex CDK9-Cyclin K stops the replication of HIV-1, because 
cyclin K doesn’t bind to TAT sequence (Fu et al., 1999). 
In precedent work it was demonstrated that CDK9 together to 
MyoD is on the promoter of p21 gene in C2C12 cells induced to 
differentiate. 
We can suppose that cyclin K is the specific regulator, in vivo, of 
the CDK9-55 kinase and the complex CDK9-55/cyclin K regulates 
pathways of arrest and cellular differentiation, that are present 
during fetal development phase, that is characterized by synthesis 
process and muscular growth. 
Being involved in the transition between cell proliferation and 
growth arrest in the myogenic program (Gurung and Parnaik, 2012), 
we have examined the in vivo expression of cyclin D3 during 
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muscle differentiation. Our results have displayed high expression 
levels of cyclin D3 throughout fetal myogenesis, in concomitance 
with the expression of p21 gene, arguing for a role in terminally 
differentiated myotubes. 
The fact that the different cyclin genes (cyclin T1, T2, K, D3) can 
function as CDK9 regulatory subunits suggest that CDK9 might 
associate with functionally different complexes and thereby 
participate in different cellular process. 
In order to discriminate the properties of isolated myoblasts during 
limbs development in vitro experiments were conduced. 
In vitro we observed that the expression of CDK9-55 isoform 
increases during differentiation both embrional and fetal myoblasts, 
while for CDK9-42 isoform it possible to observe that its levels are 
stable during proliferative and differentiative phase, begins  to 
decrease with the progress of differentiation program. 
These data permit us to conclude that the expression of two 
isoforms of CDK9 is present in embrional and fetal myoblasts, and 
their timing of expression defines their likely role: CDK9-42 
isoform prevails during proliferative phase and/or during the 
myogenic determination, while the CDK9-55 isoform has a specific 
role during differentiation. 
On embrional and foetal myoblasts the expression of different 
cyclins was analyzed, obtained results demonstrated that only cyclin 
T2 is expressed during differentiation of embrional and fetal 
myoblasts.  
Data reported in scientific reports demonstrated that cyclin T2 and 
N-terminal region of CDK9, interacting with bHLH domain of 
MyoD, allow the formation of a complex ale to stimulate the 
transcription of specific genes (Simone et al., 2002). In this 
complex, cyclin T2 interacts physically with MyoD that is 
phosphorylated by CDK9. 
Liu and Hermann demonstrated that, in Hela cells, was present in 
immunoprecipitate containing both CDK9-42 and CDK9-55, 
although the levels of associated cyclinT1 was significantly lower 
in the 55k complexes. In our experiments we observed that cyclin 
T1 is expressed during proliferative phase in embrional and fetal 
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myoblasts suggesting its interaction with CDK9-42, the isoform 
more expressed in this phase. 
Cyclin T1 and cyclin T2 differ for the carboxy terminal domains 
and Peng et al. (1998) have found that removal of this region of the 
cyclin T2 significantly reduced the ability of the CDK9/cyclin T2 to 
phosphorylate the CTD of RNA polII and function in transcription. 
The different carboxy terminal domains of two cyclins could 
explain the different expression level of these cyclins in these 
experiments. 
We analyzed also the cyclin H expression both in vivo and in vitro 
experiments: cyclin H complexed with CDK7 appear to be involved 
in transcription regulation, rather than cell cycle control and they 
are commonly found in zebrafish embryo cells. In zebrafish it was 
observed that cyclin H is present in ovary, raising the possibility 
that cyclin H mRNA might be maternally inherited. The importance 
of cyclin H during embryogenesis is supported by the fact that the 
injection of cyclin H DN mRNA into embryos disturbed normal cell 
cycle or transcription, inducing apoptosis. The transcription of 
cyclin H in rat neurons was increased primarily after ischemia, 
suggesting additional roles for cyclin H in neurons, other than cell 
cycle regulation and DNA repair (Liu et al., 2007). 
In our experiments the levels of cyclin H expression are stable 
during embrional and foetal myogenesis (in vivo analysis), while in 
vitro it is expressed at low levels only during differentiative phase 
of embrional myoblasts.  
A similar profile of expression it was observed for cyclin L, that 
complexed with CDK-11 is involved in splicing process.  
The different expression pattern of these cyclin partners between in 
vitro and in vivo analysis maybe due to  the lack, in in vitro system, 
of stimuli such as  innervation and circulating hormones, 
determining homeostasis in the organism. Thus, further 
investigations about external factors influencing their expression are 
required. 
In scientific articles is reported that CDK9 is activated by 
interaction with some members of cyclins family, by 
autophosphorylation in different residues of threonine and serine, 
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T186, S347, S362, S363, and acetylation of histones (the 
acetylation of CDK9 enhances its ability phophorylate the CTD of 
polII and promotes transcription elongation), while it inactivated by 
autophosphorylation in T29 and  by interaction with 7SKsnRNA 
and HEXIM1. 
In this work we started to study an inhibitory transcriptional factor, 
the interaction between 7SKsnRNA and HEXIM1 with CDK9.  
In the cells p-TEFb  exists in two forms, an active form composed 
by CDK9 and its cyclin partner and an inactive form composed by 
7SKsnRNA and Hexim1 complexed with CDK9/cyclin. P-TEFb is 
uniquely regulated by the reversible association with 7SKsnRNA 
and Hexim proteins. The relative partitioning into active an inactive 
complexes is a highly dynamic process that is central to the global 
regulation of cells growth and differentiation (Zhou et  al., 2006). 
It is known that 7SKsnRNA is stable when it is dissociated by 
Hexim1, while when it binds to Hexim1 promotes a major 
conformational change allowing the C-terminal domains of the 
proteins to interact with N-terminal domains of cyclin T. 
In the first step of this analysis we studied the expression of 
7SKsnRNA on total extract of C2C12, and we observed that 
7SKsnRNA is expressed in C2C12 cells during proliferative phase, 
while it isn’t expressed during differentiation. For Hexim1, indeed, 
we observed that is expressed in C2C12 at the 5th day of 
differentiation, when there is the presence of some myotubes. 
The study on 7SKsnRNA complexed with CDK9 demonstrates that 
7SK is present during proliferative phase, so as HEXIM1, that it is 
present during proliferative phase and in the early phase of 
differentiation of C2C12 demonstrating that in cells induced to 
differentiate CDK9 it isn’t associated with 7SKsnRNA/HEXIM1. 
The fact that Hexim1 it is associated with Cdk9 during proliferative 
phase and in the early differentiative phase (24h) could significant 
that HEXIM1 mediate the regulation of P-TEFb activity in the 
transition of C2C12 cells from growth to differentiation.  
Galatioto and colleagues demonstrated that by reducing expression 
of HEXIM1 in C2C12 cells there is an arrest in the transition of 
skeletal myoblast to myotubes, implying that Hexim1 and possibly 
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its association with components of P-TEFb are obligatory to the 
transition. In the same study it was observed that MyoD is 
associated with Hexim1 in the early phase of differentiation, 
suggesting that hexim1 is recruited by MyoD to offer an 
environment optimal for repression of proliferative genes and 
allowing the transition of myoblasts to myotubes  (Galatioto et al., 
2010). 
In order to verify the role of two CDK9 isoforms in the innervation 
process sciatic nerve transaction was performed. The tibialis and 
quadriceps, muscle innervated by sciatic nerve, were collected and 
used for analysis. 
During development of muscle neurons grow out towards the 
muscle fibers, which play an attractant role in axon guidance and 
the establishment of innervation. This includes both sensory 
innervation through the intrafusal fiber of muscle spindles, which 
retain a more embryonic contractile protein phenotype even in the 
adult and motor innervation of muscle fibers which drives 
contraction. The establishment of definitive neuromuscular 
junctions and excitation- contraction coupling is associated with 
secondary or fetal myogenesis. 
The innervation of the muscles in development begins shortly after 
the fibers begin to form. On the newly- formed muscle fibers can be 
observed widespread expression of the acetylcholine receptor 
(AchR) between developmental stages E12 and E14 dpc, an 
organization of AchR clusters to guide the ramifications of the 
motor nerves to the future synaptic sites (Witzemann, 2006). During 
the following days of development are witnessing a sequential 
elimination of multiple axons, with the exception of one, which 
innervate a single muscle fiber (Biressi et al ., 2007). During this 
time there is the maturation of neuromuscular junctions that ends 
around the stadium E17 dpc, the AchRs are progressively focused 
on the post- synaptic membrane and stabilize the neuromuscular 
junction ( Witzemann, 2006) 
Innervation is critical for growth and maintenance of muscle fibers, 
and denervation is well known to cause muscle atrophy. A loss of 
trophic support to the muscle following denervation, in absence of 
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neural activity muscle mass decreases, along with a reduction in 
specific force, fiber diameter and fibers number. 
In our experiments we analyzed the expression of two CDK9 
isoforms after a week and a month by denervation, and we observed 
that in regeneration process there is an increase of CDK9-55 
expression, compared to CDK9-42, suggesting its involvement in 
the innervation process. After the denervation in the muscle there is 
an increase of transcriptional factors expression, with an increase of 
myogenin. The myogenin increase gradually after few days from 
denervation, stimulating the transcription and the expression of 
some genes, as Ach receptor. 
Because in vivo analysis on limbs at different time of development 
it was observed that at the time E14,5, point of switch between 
embrional and fetal myogenesis, there is an inverse correlation of 
two CDK9 isoforms. In the specific CDK9-42 starts to decrease, 
while CDK9-55 increases gradually, in this phase there is, also, the 
innervation of the muscle and the passage between slow and fast 
fibers. Those preliminary data, together to the fact that CDK9-55 is 
the isoform more expressed in muscle after a month by denervation, 
permit us to speculate that the CDK9-55 isoform is involved in the 
recovery phase of muscle and in the new innervation process. 
Those data permit us to conclude that the expression of two CDK9 
expression is associated at a specific cellular phenotype and  is 
correlated at a specific function. 
The expression of CDK9-42 and CDK9-55 is associated with 
embrional and foetal myoblasts in vitro, and their expression profile 
defines the specific role. CDK9-42 is correlated with proliferative 
phase and/or in the first step of myogenic determination, whereas 
CDK9-55 has a predominant role during differentiation process. 
Also in vivo CDK9-55 is expressed during the differentiation of the 
muscle, at the end of embrional phase and at the start of foetal 
phase. In this period the muscle is characterized by an intense 
growth, by the innervation and by all processes that permit the 
formation of the arts. 
During embrional myogenesis there is a prevalence of CDK9-42 
expression, during this phase there is expansion and determination 
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of muscular phenotype. The difference of expressions timing of two 
isoforms, in embrional and in fetal myoblasts, probably  is the 
consequence of extra-cellular signals, that change during the 
development of the muscle. Another the combination between 
CDK9  and  specific regulators, as the cyclins, determine a different 
function of the CDK9 isoforms during the different phase of 
myogenic development. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 63 
 
5. MATERIALS AND METHODS 
 
  
5.1 EMBRYO COLLECTION 
 
CD1 mice, obtained from the department of Histology and Medical 
Embryology of “Sapienza” University of Rome, were used for the 
following experiments. They were docile albino mice, easy to work 
with, and with a rapid growth and a high reproduction rate.  
To obtain staged embryos, pairs were set up as natural (1:1) matings 
and females checked every morning for vaginal coitum. On the day 
of coitum detection, embryos were counted as E0.5 days (12h post-
fertilization). Once vaginal coitum was detected, males were 
removed from the cage to ensure accuracy of embryonic staging. 
When the desired embryonic stage was reached (E11 to E17), 
mothers were sacrificed by cervical dislocation, the abdomen was 
shaved, the skin and surrounding areas were swabbed with 70% 
alcohol and the uterus was removed via horizontal abdominal 
incision performed using sterile dissecting instruments. The uterus 
was then washed in prewarmed (37°C) PBS supplemented with 
Ca2+/Mg2+ (Dulbecco’s Phosphate Buffered Saline with CaCl2 
and MgCl2; Sigma-Aldrich, St. Louis, MO, USA) before being 
placed into a small Petri dish containing PBS with Ca2+/Mg2+ 
prior to dissection. E11 to E17 embryos were dissected from the 
uterus using a dissecting microscope and placed individually into 
Petri dishes containing PBS with Ca2+/Mg2+ ready to be 
microdissected.  
 
 
5.2 EMBRYO AND FETAL LIMBS PREPARATION FOR IN 
VIVO ANALYSIS  
 
Individual embryos were further dissected to isolate skeletal 
muscles. The embryo head was then removed via an incision along 
the length of the neck. Then, hind and forelimbs were dissected out. 
The limb muscle dissection was quicker for E10.5-E12.5 mouse 
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embryos, although embryo limbs were small in size and they had to 
be removed carefully, making an incision on the back at the level of 
the limb attachment points and then taking them off with insulin 
needles. It was instead more difficult for embryos in fetal phase 
(E14.5-E17.5), where limb muscles had been already coated by the 
epidermis and connective tissue, and cartilage/bone had already 
developed. For this reason, in older embryos (E14.5-E17.5) it was 
necessary to remove cartilage/bone and peel off the dermis prior 
limb muscle dissection.  
Once dissected out, embryo or fetal limb muscles were placed into 
an eppendorf containing  prewarmed (37°C) PBS supplemented 
with Ca2+/Mg2+ and centrifuged at 1200 rpm for 7 min. The 
supernatant was removed and the pellet was washed in prewarmed 
(37°C) CMF-PBS (Dulbecco’s Calcium and Magnesium Free 
Phosphate Buffered Saline; Sigma-Aldrich) to remove salt residues 
due to PBS washing, followed by centrifugation at 1200 rpm for 7 
min. The supernatant was removed and the pellet was submitted to a 
second CMF-PBS washing. Eventually, CMF-PBS was discarded 
and the pellet was immediately stored at -80°C or submitted to 
RNA/proteins extraction.  
 
 
5.3 PREPARATION OF EMBRYONIC LIMB (E11, E12) 
PRIMARY CULTURES  
 
Skeletal muscle cells obtained by the above described procedure can 
be used to set up embryonic limb primary cultures. The mentioned 
procedure was performed under sterile conditions, using sterile 
materials and reagents and working in class II vertical laminar flow 
biological cabinet.  
The pellet was resuspended four times with different amounts of 
medium [Dulbecco's Modified Eagle Medium (DMEM; Sigma-
Aldrich), 10% Fetal Bovine Serum (FBS; Sigma-Aldrich), 2% L-
Glutamine (L-Glut; Sigma-Aldrich), 5ml/l Penicillin/Streptomycin 
(P/S; Sigma-Aldrich)], then left to settle in the incubator at 37°C for 
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5 min and each time the surnatant containing cells was collected 
into a falcon.  
Cells were counted using the Burker chamber and resuspended in an 
adequate medium volume considering 300.000 cells/200 µl. At this 
point, the bubble method was applied. Only 200 µl medium 
containing 300.000 cells were cultured in the middle of a 60 mm 
plate pre-coated with collagen. Cells were left to incubate at 37°C 
for 3 hours. At the end, the remaining medium (2.8 ml) was 
gradually added with a 1000 µl pipette.  
24h post plating, cells were washed with CMF-PBS. Some 
proliferating cells were stopped, whereas other cells were allowed 
to differentiate in the same cell-medium reported above, and 
stopped at the pre-established time (3 or 5 days post plating) 
removing the medium, washing cells with CMF-PBS twice and 
detaching them with a scraper. Cells were then collected in a 
microcentrifuge tube and centrifuged at 1200 rpm for 10 min. The 
supernatant was removed, whereas the pellet was stored at -80°C or 
submitted to RNA/proteins extraction. 
 
 
5.4 PREPARATION OF FETAL LIMB (E16, E17) PRIMARY 
CULTURES  
 
Skeletal muscle cells obtained with the procedure described above 
can be used to set up fetal limb primary cultures.  
The pellet was placed on a 100 mm plate cover and triturated until a 
homogeneous slurry was obtained (Mechanical Digestion). It was 
transferred into a 15 ml falcon and 0.05% trypsin in CMF-PBS was 
added up to a 10 ml final volume. The falcon was placed under 
shaking in a thermostatic bath at 37°C for 45 min (First Enzymatic 
Digestion). At the end, suspended muscle cells were left to settle at 
room temperature (occasionally a centrifugation step was required). 
The supernatant was filtered through a 40 µm filter and transferred 
into a 50 ml falcon containing 5 ml horse serum (HS; Sigma-
Aldrich) necessary to supply cells with nutrients, to reduce cell 
stress and to inactivate trypsin. 0.05% trypsin in CMF-PBS was 
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added to the sediment up to a 10 ml final volume. The sediment was 
resuspended and placed under shaking at 37°C for 10 min (Second 
Enzymatic Digestion), and then to settle at room temperature for 
other 10 min. The supernatant was filtered and transferred into the 
same previous falcon. This procedure was repetead for one more 
time (Third Enzymatic Digestion).  
The supernatant resulting from the three enzymatic digestions was 
centrifuged at 1200 rpm for 12 min. The supernatant was removed 
and the pellet was resuspended in 3 ml medium [Dulbecco's 
Modified Eagle Medium (DMEM; Sigma-Aldrich), 2% L-
Glutamine (L-Glut; Sigma-Aldrich), 10% Horse Serum (Sigma-
Aldrich), 3% Chick Embryo Extract (produced in-house)], which 
were cultured in a 60 mm plate and left to incubate at 37°C for 3 
min. This pre-plating step was necessary to remove non-muscle 
cells, such as blood cells. At the end, the medium volume was 
recovered and cell-counting was performed using the Burker 
chamber. Cells were resuspended in an adequate medium volume 
considering 300.000 cells/200 µl. At this point, the bubble method 
was applied. Only 200 µl medium containing 300.000 cells were 
cultured in the middle of a 60 mm plate pre-coated with collagen, 
and they were left to incubate at 37°C for 3 hours. At the end, the 
remaining medium (2.8 ml) was gradually added with a 1000 µl 
pipette.  
24h post plating, cells were washed with CMF-PBS. Some 
proliferating cells were stopped, whereas other cells were allowed 
to differentiate in the same cell-medium reported above, and 
stopped at the pre-established time (3 or 5 days post plating) 
removing the medium, washing cells with CMF-PBS twice and 
detaching them with a scraper. Cells were then collected in a 
microcentrifuge tube and centrifuged at 1200 rpm for 10 min. The 
surnatant was removed, whereas the pellet was stored at -80°C or 
submitted to RNA/proteins extraction. 
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5.5 TOTAL RNA EXTRACTION FROM MOUSE EMBRYONIC 
AND FETAL LIMB MUSCLE TISSUES 
 
The RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia, CA, USA) 
was used for total RNA extraction from mouse embryonic and fetal 
limb muscle tissues (30-50 mg) at different stages of development. 
RNeasy Fibrous Tissue Mini Kit is designed for optimal lysis of 
fibre-rich tissues (such as skeletal muscle) and purification of high-
quality total RNA, which can be difficult due to the abundance of 
contractile proteins, connective tissues and collagen, which can be 
removed thanks to proteinase K supplied by the RNeasy Fibrous 
Tissue Mini Kit. 
Limb muscle tissues were lysed and homogenized in 300 µl Buffer 
RTL containing β-Mercaptoethanol (10 µl β-ME per 1 ml Buffer 
RTL). Lysates were carefully pipetted into new microcentrifuge 
tubes and diluted with 590 µl RNase-free water. 10 µl proteinase K 
solution were added to lysates, mixed throughly by pipetting and 
incubated at 55°C for 10 min. Then, lysates were centrifuged at 
10.000 x g for 3 min at 20-25°C. The surnatant was carefully 
removed and pipetted into a new 1.5/2 ml microcentrifuge tube. 450 
µl of 96-100% ethanol were added to cleared lysates and mixed well 
by pipetting. Samples were transferred onto the RNeasy Mini spin 
column (where RNA bound to the silica membrane) placed in a 2 
ml collection tube, and centrifuged at 8.000 x g for 15 sec at 20-
25°C. The flow-through was discarded.  
350 µl Buffer RW1 were added to the RNeasy spin column and 
centrifuged at 8.000 x g for 15 sec at 20-25°C to wash the 
membrane. The flow-through was discarded.  
10 µl DNase I stock solution were added to 70 µl Buffer RDD, 
mixed by gently inverting the tube (DNase I is especially sensitive 
to physical denaturation), and spinned to collect residual liquid from 
the sides of the tube. The DNase I incubation mix (80 µl) was added 
directly to the RNeasy spin column membrane, and left at room 
temperature for 15 min. 
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350 µl Buffer RW1 were added to the RNeasy spin column and 
centrifuged at 8.000 x g for 15 sec at 20-25°C. The flow-through 
was discarded.  
500 µl Buffer RPE were pipetted onto the RNeasy spin column and 
centrifuged at 8.000 x g for 15 sec at 20-25°C to wash the 
membrane. The flow-through was discarded. Other 500 µl Buffer 
RPE were added onto the RNeasy spin column and centrifuged at 
8.000 x g for 2 min at 20-25°C to wash and to dry the RNeasy spin 
column membrane, ensuring that no ethanol was carried over during 
RNA elution. Residual ethanol might interfere with downstream 
reactions; for this reason, following centrifugation, the RNeasy 
Mini spin column was removed from the collection tube carefully in 
order not to get in contact with the flow-through. 
The RNeasy Mini spin column was transferred into a new 1.5 ml 
collection tube. 30-50 µl RNase-free water were directly added to 
the RNeasy Mini spin column membrane and centrifuged at 8.000 x 
g  for 1 min at 20–25°C to elute the RNA.  
Eventually, extracted total RNA was stored at -80°C or analyzed by 
ND-1000 Spectrophotometer (Bio-Rad Laboratories, Hercules, CA, 
USA), a full-spectrum (220-750nm) spectrophotometer that 
measures 1 µl sample with high accuracy and reproducibility. It is 
based on a technology that employs surface tension alone to hold 
the sample in place. In addition, the ND-1000 has the capability to 
measure highly concentrated samples without dilution (50X higher 
concentration than the samples measured by a standard cuvette 
spectrophotometer). It is able to read the RNA concentration 
expressed in ng/µl using the nucleic acids and purified proteins 
wavelength ratio (260/280). In particular, the ratio of absorbance at 
260 and 280 nm is used to assess the purity of DNA and RNA. A 
ratio of ~1.8 is generally accepted as “pure” for DNA; a ratio of 
~2.0 is generally accepted as “pure” for RNA. If the ratio is 
appreciably lower in either case, it may indicate the presence of 
protein, phenol or other contaminants that absorb strongly at or near 
280 nm. 
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5.6 TOTAL RNA EXTRACTION FROM MOUSE EMBRYONIC 
AND FETAL LIMB PRIMARY CULTURES 
 
Total RNA was extracted from mouse embryonic and fetal limb 
primary cultures following the miRNeasy Mini Kit protocol 
instructions (Qiagen). 
The miRNeasy Mini Kit is designed for purification of total RNA, 
including miRNA and other small RNA molecules, from cultured 
cells and various animal and human tissues. It combines 
phenol/guanidine-based lysis of samples and silica membrane-based 
purification of total RNA. QIAzol Lysis Reagent is a monophasic 
solution of phenol and guanidine thiocyanate, designed to facilitate 
cells and tissues lysis, to inhibit RNases, and also to remove most of 
the cellular DNA and proteins from the lysate by organic extraction.  
To lyse cells directly, the cell-culture medium was discarded and 
cells were washed with PBS. 700 µl QIAzol Lysis Reagent were 
added directly to cells, and the lysate was collected with a scraper 
into a microcentrifuge tube and homogenized by vortexing for 1 
min. The homogenate was left at 15-25°C for 5 min to promote 
dissociation of nucleoprotein complexes. Then, 140 µl chloroform 
were added to the homogenate, the tube was vortexed vigorously for 
15 sec, left at room temperature for 2-3 min and then centrifuged for 
15 min at 12.000 x g at 4°C. After centrifugation, the sample was 
separated into 3 phases: an upper, colorless, aqueous phase; a white 
interphase; and a lower, red, organic phase. RNA partitioned to the 
upper, aqueous phase, while DNA partitioned to the interphase and 
proteins to the lower, organic phase or the interphase.  
The upper, aqueous phase was recovered and transferred into a new 
collection tube. 525 µl  100% ethanol were added and mixed 
throughly by pipetting up and down several times. The sample was 
then applied to the RNeasy Mini spin column (where the total RNA 
bound to the membrane, and phenol and other contaminants were 
efficiently washed away), and centrifuged at 8.000 x g for 15 sec at 
15-25°C. The flow-through was discarded and 500 µl Buffer RPE 
were pipetted onto the RNeasy Mini spin column and centrifuged at 
8.000 x g for 15 sec to wash the column. The flow-through was 
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discarded. Other 500 µl Buffer RPE were added onto the RNeasy 
Mini spin column and centrifuged at 8.000 x g  for 2 min to dry the 
RNeasy Mini spin column membrane, ensuring that no ethanol was 
carried over during RNA elution.  
The RNeasy Mini spin column was transferred into a new 1.5 ml 
collection tube. 30-50 µl RNase-free water were directly added onto 
the RNeasy Mini spin column membrane and centrifuged at 8.000 x 
g  for 1 min at 20-25°C to elute the RNA.  
Extracted total RNA was stored at -80°C or analyzed by NanoDrop. 
 
 
5.7 RNA IMMUNOPRECIPITATION ASSAY 
 
The C2C12 cells were grown in DMEM supplemented with 20% 
FBS (Growth medium, GM) and differentiated in DMEM  
supplemented with 2% HS (Differentiation Medium, DM). 900000 
cells for each time of development are collected. The cells are 
treated with trypsin, the digestion is stopped with the addition of 
medium and the cells are spin at 400g for 5 minutes. The cell pellet 
is washed  for two times with 10 ml of PBS and the cells are spin 
again. 
The cell pelelt is resuspended in 10 ml of PBS and 270 µl of 37% 
formaldehyde (Sigma Aldrich). The cells are incubat for 30 minutes 
at 37°C on rocking platform. To stop cross-linking 1.4 ml of 2M 
sterile glycine are added, the cells are incubate 5minutes at 37°C; 
then they are spinned and the pelelt is washed for two times with 
PBS. The pellet is resuspende in 1ml of ice-cold 2x Cell Lysis 
buffer, containing 1x Protease inibitor coktail (20mM Na-PB pH7, 
300mM NaCl, 5mM MgCl2, 4mM EDTA, 2mM DTT, 10 mg/ml 
Heparin, 10% glycerol, 2%Na-deoxycholat, 0,2% SDS, water). The 
cells are placed on ice for 1 hours, the cell lysate is spnned at 10000 
g for 15 minutes at 4°C. The supernatant is collected. The samples 
are sonicated at 50% amplitude for 15 sec. in ice, to 1 ml cell lysate 
is added 100 µl of 10x Dnase buffer, 5 µl RNasin and 10 µl of 
RNase-free DNase. The lysate is incubated at 37°C for 15 minutes, 
then the 40 µl of 0,5 M EDTA are added to stop the reaction, and 
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the samples are centrifugated 5 minutes at 14000 rpm; the 
supernatant is collected. To cell lysate 5µg of antibody ( a sample is 
used as negative control, using IgG) are added, thelysate I incuaed 
at 4°C O/N. 50   µl of washed Protein A/G are added, and the lysate 
is centrifugated at 10000g for 30 seconds at 4°C. The obtained 
pellet is washed 5 times with 500  µl of 1x Cell Lysis buffer. After 
the last wash the supernatant is aspirated, and 85µl of protein-RNA 
elution buffer (100mM Tris-HCl pH8, 10mM Na2-EDTA, 1% SDS, 
wathr) are added. The samples are incubated 10 inutes at 37°C:  20 
µl of eluate are conserved for Western blotting analysis. 
To 150 µl eluates are added 6 µl of 5 M NaCl and 20 µg proteinase 
K. Incubation at 42°C for 1hour to digest cross-linked polypeptides, 
and successive incubation at 65°C for 1 hour to reverse the 
formaldeyde  cross-links. 
At the sample 100 µl DEPC-H2O, 25 µl 3M Na-acetate and 20 µg 
glycogen are added.  
The RNA is extracted with the method Phenol/ CHCl3 (1:1), 625 µl 
ethanol are added and the RNA is precipitated at -80°C O/N. 
The extracted RNA is analyzed with RT-PCR assay. 
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Figure 30: Schematic representation of RNA-immunoprecipitation assay. 
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5.8 RNA RETRO-TRANSCRIPTION  
 
The iScriptTM complementary DNA (cDNA) Synthesis Kit (Bio-
Rad Laboratories) was used for the reverse transcription of total 
RNA extracted from mouse limb muscles and embryonic/fetal 
primary cultures. This kit allows to obtain high-quality single-strand 
cDNA in a simple and efficient manner thanks to the presence of a 
single reaction mixture that reduces the reaction time, increases the 
experimental reproducibility and minimizes the cross contamination 
risk. 
The cDNA synthesis requires the preparation of a mixture 
composed of 4 µl 5X iScriptTM Reaction Mix [oligo(dT) and 
random hexamer primers1, MgCl2, DTT, dNTPs, RNase inhibitor, 
buffer], 1 µl iScriptTM Reverse Transcriptase, 500 ng RNA sample, 
and Nuclease-free water up to a 20 µl final volume.  
The mixture was placed in the thermocycler PTC-200 (Bio-Rad 
Laboratories) and submitted to following steps: 5 min at 25°C; 30 
min at 42°C; 5 min at 85°C and finally held at 4°C. 
The cDNA was stored at -20°C or analyzed by Real-Time 
quantitative Reverse Polymerase Chain Reaction (Real-Time qRT-
PCR). 
 
5.9 REAL-TIME QUANTITATIVE REVERSE 
TRANSCRIPTION POLYMERASE CHAIN REACTION (REAL-
TIME QRT-PCR) 
 
The cDNA was analyzed by Real-Time qRT-PCR using the 
Opticon 2 real-time PCR cycler (Bio-Rad Laboratories) and the 
program Opticon 3.2 (Bio-Rad Laboratories).  
The qRT-PCR is used to amplify and simultaneously quantify a 
targeted DNA molecule, enabling both detection as the reaction 
                                                          
1
 The presence of both oligo(dT) and random hexamer primers ensures the 
reverse transcription of all RNA sequences including those that do not have 
poly(A)-tails, and the generation of full-length cDNA, respectively. In fact, 
random hexamers bind along the entire length of the RNA, while oligo(dT) 
primers are designed to bind at the beginning of the poly(A)-tail; therefore they 
are not specific for mRNAs. 
 74 
 
progresses in real time and quantification (as absolute number of 
copies or relative amount when it is normalized to additional 
normalizing genes). Two common methods used for products 
detection in real-time PCR are non-specific fluorescent dyes that 
intercalate with any double-stranded DNA, and sequence-specific 
DNA probes consisting of oligonucleotides that are labeled with a 
fluorescent reporter which allows detection only after hybridization 
of the probe with its complementary DNA target.  
In particular, Syber Green (Bio-Rad Laboratories) or TaqMan 
probes (Applied Biosystems, Foster City, CA, USA) were used for 
the sample cDNA amplification following manufacturer’s 
instructions. 
The reaction mixture for cDNA amplification using TaqMan probes 
was made up of 1 µl Taqman probe (Life Technologies, Carlsbad, 
CA, USA), 9 µl RNase-free water (Life Technologies), 10 µl 
SsoFastTM Probes Supermix (Bio-Rad Laboratories) and 1 µl 
cDNA.  
The qRT-PCR steps were: 2 min at 95°C (activation), 40 cycles of 
10 sec at 95°C (denaturation) and 20 sec at 60°C (annealing and 
elongation).  
The reaction mixture for cDNA amplification using Syber Green 
was composed of 2.5 µl forward primer, 2.5 µl reverse primer, 10 µl 
SsoFastTM EvaGreen Supermix, 4 µl RNase-free water (Life 
Technologies) and 1 µl cDNA. 
The qRT-PCR steps were: 2 min at 95°C (activation), 40 cycles of 
10 sec at 95°C (denaturation) and 20 sec at the pre-established 
annealing temperature (annealing and elongation). 
Primers of GAPDH and T1, T2a, H, L, D3 cyclins (Table 2) were 
designed on the base of gene sequences available on the NCBI 
website (www.ncbi.nlm.nih.gov). The remaining sequences are 
custom TaqMan Probes pre-designed by Applied Biosystems.  
The cDNA levels were normalized to those of the housekeeping 
GAPDH gene and calculated relatively to controls by the 2-∆∆Ct 
method (Live and Schmittgen, 2001). 
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GAPDH: 5’-TCGGAGTCAACGGATTTG-3’ 
                 5’-GGATCTCGCTCCTGGAAG-3’ 
 
CYCLIN T1: 5’-GAATGAGAGTGCTTGTGTGAG-3’ 
                      5’-AAACCAGAGGAGATAAAAATG-3’ 
 
CYCLIN T2a: 5’-GACATGTCCGTAGCCCACCTG-3’ 
                        5’-GCATCCTCGGAAAGACACAGC-3’ 
 
CYCLIN H: 5’-CCTCGGATAATAATGCTTAC-3’ 
                    5’-TCATAGCCTTTCCTCTTC-3’ 
 
CYCLIN L: 5’-CGAGATTGTTGCTATGGC-3’ 
                   5’-CACTGGCTTCTCCTTGGG-3’ 
 
CYCLIN D3: 5’-CAGCGTGTCCTGCAGAGTT-3’ For 
                      5’-CCTTTTGCACGCACTGGAA-3’ Rev 
 
7SKsnRNA: 5’- ATCTGTCACCCCATTGATCG-3’  
                     5’- GCGCAGCTACTCGTATACCC-3’ 
 
CDK9-55     Sonda Taqman (Applied Byosistems): 
CDK9M55KDA-ANY 445370 20X MIX  
 
CDK9-42     Sonda Taqman (Applied Byosistem) : 
CDK9M42KDA-ANY 445370 20X MIX  
 
The statistical test calculates the p-value of every detector  
compared in the analysis.  
Comparison of group was performed using ANOVA test. The 
control group was compared to the individual experimental group; 
differences were considered significant at P<0,05. 
Results were analyzed using GraphPad PRISM  (version 5,00, 
March 2007). 
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5.10 PROTEIN EXTRACTION  
 
For protein extraction, limb muscle tissues and embryonic/fetal 
primary cultures pellets were washed in PBS and then lysed in 
RIPA BUFFER [50 mM Tris-HCl pH 7.5, 50 mM EDTA pH 8, 150 
mM NaCl, 1% (v/v) Nonidet P-40] supplemented with protease 
inhibitors (0.3 mM PMSF and Complete, Mini, EDTA-free Protease 
Inhibitor Cocktail Tablets; Roche, Basel, Switzerland) and 
phosphatase inhibitors (2 mM NaOV, 10 mM NaF). Lysates were 
transferred into new 1.5/2 ml microcentrifuge tubes, left to incubate 
on ice for at least 30 min and then centrifuged at 12.000 x g for 20 
min at 4°C. The surnatant containing the protein extract was 
transferred into a new eppendorf and stored at -80°C or submitted to 
Bradford protein assay.  
 
 
5.11 DETERMINATION OF PROTEIN CONCENTRATION 
 
The Bradford protein assay (Bio-Rad Laboratories) was used to 
determine the extracts protein concentration. It is a colorimetric 
assay based on the proportional binding of the Coomassie Brilliant 
Blue G-250 dye to proteins (Bradford, 1976). Coomassie absorbs at 
465 nm, but this value shifts to 595 nm when it binds to proteins. 
The absorbance increase at 595 nm is proportional to the amount of 
bound dye and, thus, to the concentration of proteins present in the 
sample.  
The protein concentration was determined using a standard curve in 
which the increasing concentration values of the BSA (bovin serum 
albumine) standard protein solutions were reported in x-axis, 
whereas the corresponding absorbance values in y-axis. By 
calculating the BSA absorbance in concentration-known solutions, 
it was possible to determine the samples protein concentration.  
Based on the results, a relative normalization was made versus the 
sample with the lowest protein concentration, in order to use the 
same amount of total proteins in the following protein analysis. 
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5.12 POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-
PAGE) 
 
The protein separation was performed in polyacrylamide gels 
following Laemmli instructions (Laemmli, 1970), using a Mini 
Protean 3 Cell (Bio-Rad Laboratories). The gels were made at an 
acrylamide/bis-acrylamide concentration of 10% for the separation 
gel, and 4% for the stacking gel, whose composition is reported 
below:  
 
 
 
COMPONENTS OF 10% SEPARATION GEL VOLUM 
H2O  4 ml 
1.5 M Tris-HCl pH 8.8 2.5 ml 
30% (w/v) Acr/Bis  3.3 ml 
10% (w/v) SDS (Sodium Dodecyl Sulfate)  0.1 ml 
10% (w/v) APS (Ammonium Per-Sulfate)  0.1 ml 
TEMED (N,N,N′,N′-Tetramethylethylenediamine) stock 0.01 ml 
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COMPONENTS OF 4% STACKING GEL VOLUM 
H2O  3.4 ml 
1.5 M Tris-HCl pH 6.8 0.63 ml 
30% (w/v) Acr/Bis  0.83 ml 
10% (w/v) SDS (Sodium Dodecyl Sulfate)  0.05 ml 
10% (w/v) APS (Ammonium Per-Sulfate)  0.05 ml 
TEMED (N,N,N′,N′-Tetramethylethylenediamine) 
stock 
0.005 ml 
 
In order to denature proteins to promote their separation in gels, 
loading buffer (LB) [50 mM Tris-HCl pH 6.8, 10% (w/v) glycerol, 
0.5% (w/v) SDS, 0.025% (w/v) bromophenol blue, 10% (v/v) β-
mercaptoethanol] was added to protein extracts. Molecular weight 
standards from 12 to 225 kDa (Precision Plus ProteinTM All Blueb 
Standards, Bio-Rad Laboratories) and protein extracts were then 
boiled for 5 min at 95°C, transferred on ice, and finally loaded  on 
the polyacrylamide gel. In particular, equal amounts of protein 
extracts (25-50 µg) for each sample were loaded onto the gel and 
separated at 90V in running buffer [25 mM Tris-Base, 192 mM 
glycine, 0.1% (w/v) SDS]. At the end, they were transferred onto a 
PVDF membrane (Bio-Rad Laboratories) as described by Towbin et 
al., 1979. The electrotransfer was perfomed in transfer buffer [25 
mM Tris-Base, 192 mM glycine, 20% (v/v) methanol] at 
20V/60mA overnight at 4°C, using the Bio-Rad Transblot system. 
In order to confirm the protein transfer from the polyacrylamide gel 
to the PVDF membrane, proteins were reversibly stained with 
Ponceau Red, which was subsequently washed away with TBST 
[0.1 M Tris-HCl pH 7.5, 0.15 M NaCl, 0.1% Tween 20 pH 7.4]. 
 
 
5.13 IMMUNO-BLOTTING 
 
To block non-specific binding sites, the PVDF membrane was 
incubated with 5% non-fat powdered dry milk in TBST for 1h at 
room temperature. The membrane was then incubated with primary 
antibody diluted in 5% non-fat powdered dry milk in TBST 
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overnight at 4°C (Table 3). It was then washed three times for 10 
min in TBST and incubated with secondary antibody conjugated 
with peroxidase diluted in 1% non-fat powdered dry milk in TBST 
for 1h at room temperature. Primary antibody: CDK9 (1:200; Santa 
Cruz, CA), MyoD (1:100; 5.8A, BD), Myogenin (1:100; F5D, 
Dako), MHC (1:20; MF20, Fishman), Desmin (1:100; Sigma), 
Embyonic myosin (1:100; BF-G6, Schiaffino, 1989),  Fast myosin 
(1:300; Sigma), Slow myosin (1:300; Sigma), Pax3 (1:100; 
Hybridoma Bank), Pax7 (1:100; Hybridoma Bank), Cyclin T1 
(1:100; Santa Cruz, CA), Hexim 1, Tubuline(1:250; Sigma), β-
Actine (1:300; Sigma). Three more washings in TTBS were 
performed and the membrane was then incubated with the 
peroxidase substrate (SuperSignal® West Pico Chemiluminescent 
Substrate; Thermo Scientific, Rockford, USA), whose 
chemiluminescent product allowed the detection of proteins bound 
by the antibody.  
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